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1.1. T cell function and activation 
The immune system defends the organism against pathogens, autoimmunity or 
cancer and clears established infections. It consists of different cell types that 
function together and communicate with each other in order to provide protection. 
The importance of the immune system becomes obvious with disturbances or 
immune deficiencies resulting in severe, even life-threatening consequences as 
autoimmune diseases, serious and chronic infections. The lymphatic system provides 
optimal surroundings for quick immune responses. Immune cells meet in the lymph 
nodes while circulating in the host and come in touch with other immune cells, which 
is a central aspect during all immune responses. This allows a targeted immune 
response adjusted to different pathogens.  
The immune system is divided in adaptive and innate immunity. Cells of the latter 
system recognize general pathogenic patterns via invariant receptors as TOLL-like 
receptors and provide the first line of defence against pathogens. The adaptive 
immune system consists of lymphocytes as B and T cells having a variable repertoire 
of receptors to recognize specific antigens. Antigen presentation is the first important 
step for an immune reaction, leading to proliferation of antigen-specific cells and the 
improvement of immune responses (Friedl et al., 2005). Antigen presenting cells 
(APCs) take up pathogens or –derived proteins and present it to T and B cells. 
During this very first step the nature of the immune response is determined (Fig. 1). 
At this contact the lymphocytes are stimulated by their cognate antigen and receive 
co-stimulatory signals driving them to different effector cell phenotypes. B cells exert 
their functions by antibodies (humoral immunity), that can opsonise pathogens and 
subsequently lead to their clearance by phagocytotic cells such as macrophages. T 
cells on the other hand fulfil cell-mediated immunity. They can be divided into CD4+ T 
cells, which comprise about two third of all T cells, and CD8+ cytotoxic T cells and 
both types recognize antigen by binding of the T cell receptor (TCR) to a peptide in 
the context of MHC-molecules. CD4-molecules exclusively allow the interaction of 
TCR:MHC class II (Gay et al., 1987), whereas CD8-molecules interact with MHC 




Fig. 1 Immunological synapse. T cell activation requires two distinct signals. The first signal is 
provided by the cognate antigen in context of MHC-II-molecules (1). To become fully activated a 
second signal is needed via interaction of CD28 with the costimulatory molecule CD80 (2). After 
activation rapid cytoskeletal rearrangements take place by dephosphorylation of ERM proteins and 
the cell metabolism adapts to the higher energy demand by switching from oxidative phosphorylation 
as major energy source to glycolysis (3). Adapted from (Friedl et al., 2005). 
 
T cells evolve in the thymus and are positively selected for MHC recognition by the 
TCR and negatively to prevent survival of auto-reactive T cells. Special APCs in the 
thymus, the medullary thymic epithelial cells (mTECs), present auto-antigen to 
developing T lymphocytes and every T cell recognizing self-structures is sorted out 
(Hinterberger et al., 2010). mTECs express high amounts of major histocompatibility 
complex (MHC) molecules and peripheral antigens which are expressed in the 
thymus only for the purpose of T cell selection. This step in T cell development is 
crucial, because auto-reactive T cells that escape into the periphery can cause 
severe autoimmune diseases like Type 1 Diabetes, Multiple Sclerosis (MS) or 
Crohn’s disease.  
To prevent immune reactions without inflammatory environment, T cell activation in 
the periphery requires two distinct signals (Bretscher and Cohn, 1970; Bretscher, 
1999; Fig. 1). The first signal, binding of the cognate antigen in MHC molecule 
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context (class I for CD8+ T cells, class II for CD4+ T cells), is necessary but not 
sufficient for T cells activation. A second, co-activatory signal is needed as the 
binding of CD28 on the T cell side to CD80 (B7) on APCs, in its absence T cells 
become anergic (Lenschow et al., 1992; Sperling and Bluestone, 1996).  
CD4+ T cells are also called T helper cells (Th cells), as they assist B cells to fulfil 
their appropriate functions. They are primed to different subtypes as Th1, Th2 or 
Th17 cells during the first encounter of an antigen presented by APCs. B cells can 
secrete antibodies having the same specificity as their B cell receptor. Depending on 
the pathogen different classes of antibodies can be produced. The T cell help 
determines the isotype of the secreted antibodies to provide optimal pathogen 
defence and is mediated by soluble triggers, so called cytokines. Th1 cells stimulate 
phagocyte-mediated immunity by secretion of a special set of cytokines including 
interferon γ (IFNγ). Th2 cells induce eosinophil or mast cell mediated immunity and 
trigger the secretion of antibodies by secretion of cytokines distinct from those 
expressed by Th1 cells as interleukin-4 (IL-4), IL-5 or IL-10 (Romagnani, 1999). 
Other subsets of Th cells like IL-17 secreting Th17 cells came more and more into 
focus during the last decades as central players in autoimmune diseases. For 
example, the development of Type 1 diabetes in BioBreeding rats is linked to an 
imbalance between Th17 and regulatory T cells (Treg cells; van den Brandt et al., 
2010). 
About 5% of all CD4+ T cells are Treg cells that suppress auto-reactive or massively 
proliferating T cells (Papiernik et al., 1998). Thus, the induction peripheral tolerance 
is another central task of T cells. Because dysfunctions of the immune system 
regulation can have fatal outcomes like severe autoimmune diseases, proper T reg cell 
function is essential (Heiber and Geiger, 2012; Taguchi and Takahashi, 1996).  
CD8+ T cells, also called cytotoxic T lymphocytes (CTLs), on the other hand detect 
cells that are harbouring intracellular pathogens and eliminate them (Blanden, 1974; 
Fung-Leung et al., 1991). They recognize peptides originating from cytoplasmatic 
proteins presented on MHC-I molecules such as viral proteins. They kill the infected 
cells to stop virus production. The killing is mediated by granule exocytosis targeted 
to the infected cell releasing perforin and granzymes.  
Collectively, T cell mediated immunity and the proper control of immune responses 
are two central and essential parts during health and disease. 
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1.2. T cell morphology and migration 
Activated T cells stop to circulate in the lymph and blood vessels and have to 
extravasate into target tissues. Subsequently, they have to be re-stimulated at the 
site of inflammation. To this end, T lymphocytes must adopt a unique morphology, 
which is crucial for migration and cell-cell-interaction. In general, lamellipodiae are 
formed on the leading edge of the cell whereas an uropod is found at the opposing 
pole. Part of the cell surface receptors and lipid rafts become confined to the uropod 
where they form the distal pole complex (DPC). In contrast, other surface molecules 
like integrins and chemokine receptors are concentrated at the leading edge where 
they serve to sense chemokines during crawling (Smith et al., 2005). These structural 
features are essential to allow correct movement of T cells (Krummel and Macara, 
2006) and for directing their effector mechanisms such as the release of cytokines 
and cytotoxic molecules to the contact zone with other cells. As the cytoskeleton is 
crucial for morphological alterations to occur, inhibitors of F-actin polymerization such 
as cytochalasin D or latrunculin A were found to interfere with T cell activation and 
effector functions (Grakoui et al., 1999). 
The cytoskeleton is composed of F-actin filaments, microtubules and intermediate 
filaments. While the latter provide the mechanical force necessary for migration 
(Vicente-Manzanares and Sanchez-Madrid, 2004), the microtubule system regulates 
polarization and maintenance of F-actin-dependent structures (Sancho et al., 2002).  
 
 
Fig. 2 Effector T cell 
morphology. The cytoskeleton of 
activated effector T cells was 
visualized by staining of F-actin 
(left panel) or by visualizing β-
tubulin (right panel). The effector T 
cells show a polarized structure 
with large lamellipodiae and 
microtubule-organizing centers 
(MTOC) which is essential for 
proper T cell function (Müller et al., 
2013).  
 
Importantly, the cytoskeleton of T cells becomes reorganized within minutes after T 
cell receptor (TCR) stimulation, which involves polymerization of F-actin (Bunnell et 
al., 2001; Tskvitaria-Fuller et al., 2003; Valitutti et al., 1995), reorientation of the 
microtubule-organizing centre (MTOC) towards the immunological synapse and 
formation of the DPC (Fig. 2). Consequently, cell surface receptors are redistributed 
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and intracellular signalling complexes assembled, events that are important for the 
formation of the immunological synapse as well as for migration (Krummel et al., 
2000). The relevance of the cytoskeletal organization for proper T cell function is 
underscored by several loss-of-function studies in mice, where deficiency in 
individual cytoskeleton regulatory proteins led to impaired T cell activation, cytokine 
production and proliferation (Billadeau et al., 2007). 
 
1.3. Multiple Sclerosis 
Multiple sclerosis (MS) is the most prevalent neuroinflammatory autoimmune disease 
in the western world (Sospedra and Martin, 2005). It is characterized by severe motor 
deficits and impaired neurocognitive functions which arise as the result of focal 
demyelination and axonal loss in the central nervous system (CNS) (Hafler, 2004). 
To interfere with the progression of MS a plethora of treatment regimens have been 
developed over the years or are currently being tested in clinical trials. These include 
IFNb, glatiramer acetate (GA), small molecular weight compounds such as fumarate 
derivatives and laquinimod and monoclonal antibodies directed against leukocyte 
antigens and cytokines (Barten et al., 2010; Buck and Hemmer, 2011; Hafler, 2004; 
Noseworthy, 2003). In the case of acute disease relapses, however, treatment with 
glucocorticoids (GCs) is still the measure of choice (McDonald et al., 2001). Initially 
established as a new therapy for rheumatoid arthritis patients in the late 1940s 
(Hench, 1950), GCs later became a standard regimen to treat acute relapses in MS 
patients (Milligan et al., 1987).  
MS is a chronic neuroinflammatory disease that has significant socioeconomic 
relevance. Most often the disease develops during early adulthood with women being 
affected twice as often as men. Already in 1868 Jean Martin Charcot described 
inflammatory lesions in the CNS of patients suffering from neurological dysfunctions 
(Charcot, 1868; Hafler, 2004), and over the twentieth century it became clear that MS 
is a highly diverse disease entity. Today, we distinguish between relapsing-remitting, 
primary progressive and secondary progressive MS based on the disease course 
(Noseworthy et al., 2000). Most patients initially present with a relapsing-remitting 
form but eventually the majority of them develop a secondary progressive phase 
characterized by increasing deficits in the absence of further relapses. Only about 
10-15% of the patients suffer from primary progressive MS with continuous 
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aggravation of the symptoms from early onwards (McFarlin and McFarland, 1982a; 
McFarlin and McFarland, 1982b). In the majority of the cases, MS is believed to have 
an autoimmune pathogenesis, with auto-reactive myelin-specific T cells playing a 
dominant role. This refers to CD4+ T helper (Th) 1 and Th17 cells (Lovett-Racke et 
al., 2011) as well as CD8+ T cells (Friese and Fugger, 2005; Huseby et al., 2001), 
even though B cells are currently being re-considered as central players in this 
process (Disanto et al., 2012). Finally, antibodies and complement deposition also 
seem to contribute to the progression of the disease (Sospedra and Martin, 2005). 
 
1.4. Experimental Autoimmune Encephalomyelitis (EAE) as a model of 
MS 
Insight into the pathomechanism of MS and its treatment regimens is to a significant 
degree derived from the analysis of animal models. Experimental Autoimmune 
Encephalomyelitis (EAE) was established as the primary model of MS already 
several decades ago and is based on an observation originally made in the course of 
rabies vaccination (Zamvil and Steinman, 1990). In rare cases patients who received 
the vaccine composed of the fixed pathogen grown in rabbit brain developed a 
severe paralytic disease. Based on these findings Rivers and colleagues later 
immunized rhesus monkeys with rabbit CNS homogenate which resulted in a 
demyelinating disease that mirrors many characteristics of the human disorder and 
therefore became instrumental for studies of the pathogenesis and treatment of MS 
(Rivers TM, 1933). This eventually led to the development of EAE in which mostly 
rats and mice are immunized with myelin antigens emulsified in adjuvant (Kabat et 
al., 1947). In general, EAE is a T cell-mediated disease highlighted by the fact that it 
can be transferred to naïve animals using pathogenic CD4+ (Zamvil and Steinman, 
1990) or CD8+ T cells (Huseby et al., 2001; Sun et al., 2001). While CD4+ T cells 
alone are sufficient to induce EAE even in the absence of CD8+ T cells, many 
studies also speak in favour of an important role of CD8+ T and B cells in EAE 
(Cabarrocas et al., 2003; Ford and Evavold, 2005; Mars et al., 2011; Saxena et al., 
2008; Ziemssen and Ziemssen, 2005). Furthermore, application of new techniques 
such as intravital imaging by 2-photon microscopy has allowed insight into the 
different phases of EAE (Bartholomäus et al., 2009). This led to the discovery that a 
phenotypic change of encephalitogenic T cells into a “migratory” phenotype, 
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subsequently directing immune cell migration into the target tissue, is crucial during 
EAE development (Odoardi et al., 2012). 
One animal model cannot reflect all aspects of the complex human disease, but 
rather individual EAE models reflect different features of MS. EAE induced by 
immunization with myelin basic protein (MBP) in Lewis rats for example follows a 
monophasic disease course without significant demyelination and axonal damage, 
thereby mainly mimicking the inflammatory features of MS. In contrast, relapsing-
remitting EAE models can be induced by immunization of DA rats with myelin 
oligodendrocyte glycoprotein (MOG) or SJL mice with proteolipid protein (PLP), and 
present with massive demyelination and axonal loss. Importantly, exploiting these 
different EAE models has significantly helped in developing new drugs for the 
treatment of MS such as GA, mitoxantrone and natalizumab (Steinman and Zamvil, 
2006), and contributed to our current understanding of how high-dose GC therapy 
interferes with MS (Schweingruber et al., 2012). 
To study particularly the inflammatory phase we used the monophasic Lewis rat EAE 
model and took advantage of the possibility to isolate CNS-antigen specific effector T 
cells from these rats and to propagate them in vitro. 
1.4.1. T cell Migration in EAE 
T lymphocytes are central players in the pathogenesis of EAE and MS, and proper 
activation and polarization are essential for their functioning. In active EAE, T cell 
activation is generally achieved by the use of Complete Freund's Adjuvant (CFA), 
which stimulates antigen-presenting cells (APCs) and induces a pro-inflammatory 
milieu (Medzhitov and Janeway, 2002). In adoptive transfer EAE, T cells also have to 
be activated in order to be capable of infiltrating the CNS. In this case, however, they 
are cultured with antigen-loaded APCs in vitro prior to their transfer into naïve 
animals (Wekerle et al., 1986). Regardless of the model, T cells have to migrate to 
the site of inflammation and then cross the blood-brain barrier (BBB; Engelhardt and 
Ransohoff, 2012). 
Soluble mediators that trigger leukocyte migration are called chemokines and 
produced by a variety of immune cells as well as fibroblasts and endothelial cells 
(Jaerve and Müller, 2012; Mortier et al., 2012). Following their release chemokines 
can attach to extracellular matrix (ECM) components or specialized receptors and 
thereby form cues for migrating leukocytes. Under physiological conditions 
constitutively expressed chemokines establish gradients that guide leukocytes to 
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their appropriate location within primary and secondary lymphoid organs for which 
reason they are prerequisite for immune surveillance and maintenance of tissue 
homeostasis (Holman et al., 2011). Migration of leukocytes to their target tissues and 
lymph nodes along chemokine gradients is then followed by interaction of cell-
surface molecules on trafficking lymphocytes with their ligands on endothelial cells 
(Engelhardt, 2008). In the case of infection or tissue damage pro-inflammatory 
chemokines serve to rapidly attract leukocytes to the site of inflammation and foster 
their extravasation from the blood. More precisely, chemokines induce firm 
attachment of leukocytes such as T cells to the vessel wall at inflamed sites by 
inducing conformational changes of integrins such as LFA-1 and VLA-4, which 
consolidates interaction with their receptors ICAM-1 and VCAM-1 on endothelial 
cells. This eventually results in intraluminal crawling followed by diapedesis via the 
paracellular or transcellular pathway.  
Chemotaxis is a crucial mechanism in the pathogenesis of EAE and MS, since 
chemokines guide activated lymphocytes to the site of inflammation where they cross 
the BBB. Migration of immune cells into the CNS is best studied in transfer EAE 
models. Here, activated T cells are isolated from rats or mice after EAE induction and 
transferred into naïve recipients where they subsequently invade the CNS without 
prior activation of the host's immune system (Mix et al., 2008; Owens et al., 1998). As 
mentioned above, adhesion of immune cells to the vessel wall is mediated by 
integrins such as LFA-1 and VLA-4 (Engelhardt and Ransohoff, 2012). During EAE, 
their ligands ICAM-1 and VCAM-1 are up-regulated on cells of the BBB, the blood-
leptominingeal barrier, the choroid plexus epithelium and the blood-cerebrospinal 
fluid barrier, which could be responsible for the increased leukocyte infiltration into 
the CNS (Engelhardt and Coisne, 2011). Accordingly, EAE is ameliorated by blocking 
LFA-1 or VLA-4 (Weller et al., 1996). Of note, migration of small numbers of T cells 
across the BBB is possible in the absence of these molecules even though T cell 
polarization and crawling are mediated by binding of LFA-1 to ICAM-1 and ICAM-2 
(Steiner et al., 2010).  
1.5. Glucocorticoids (GCs) in the treatment of MS and EAE 
T cells are the most important targets of GCs in EAE and presumably MS (Wüst et 
al., 2008). For a long time it was assumed that the therapeutic efficacy of GCs mainly 
relies on induction of T cell apoptosis (Herold et al., 2006; Reichardt and Lühder, 
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2012), repression of pro-inflammatory cytokines (Baschant and Tuckermann, 2010) 
and modulation of leukocyte-endothelial interactions (Pitzalis et al., 2002). This 
notion, however, is now being called into question by accumulating evidence that T 
cell morphology and migration might also be crucial targets of GC action (Ghosh et 
al., 2009). For many years apoptosis induction was considered to be essential for the 
beneficial effects of GCs in EAE and MS (Gold et al., 2006; Pender and Rist, 2001). 
Nevertheless, increasing evidence suggests that this might be not the case. First, it 
was observed that EAE was ameliorated by GCs at a concentration that did not 
significantly induce apoptosis (Nguyen et al., 1997). Second, application of 
Compound A, a dissociating non-steroidal GR ligand, improved EAE even in the 
absence of apoptosis induction (van Loo et al., 2010; Wüst et al., 2009). Third, GCs 
inhibit activation-induced cell death (AICD), which preferentially protects effector T 
cells from GC-induced apoptosis (Baumann et al., 2005). However, loss of this 
protective effect does not seem to impact treatability of EAE by GC therapy, which 
was shown by inducing EAE in mice deficient for acid sphingomyelinase (aSMase). 
Due to the reduced IL-2 secretion by aSMase-deficient effector T cells their 
sensitivity for GC-induced apoptosis is enhanced. Consequently, one would have 
expected that GCs were more potent in ameliorating EAE in aSMase knock-out mice 
than in wildtype controls. Nevertheless, the efficacy of Dex therapy was similar in 
both genotypes (Tischner et al., 2011). Collectively, there are a number of findings 
that call the notion into question that apoptosis induction is indispensable for the 
treatment of CNS inflammation by GCs.  
GCs exert the majority of their functions by binding to the GC receptor (GR), a 
member of the nuclear receptor superfamily that resides in the cytosol sequestered in 
a heat shock protein complex. Upon hormone binding the GR is released and then 
translocates into the nucleus where it either binds to GC responsive elements 
(GREs) leading to gene transactivation or acts as a negative regulator by interacting 
with other transcription factors such as NF-kB or AP-1 (Baschant and Tuckermann, 
2010; Fig. 2). GCs can also bind to the mineralocorticoid receptor (MR) with even 
higher affinity (De Kloet and Derijk, 2004). However, expression of the MR is 
restricted to selected cell types and in many of them GCs are inactivated by 11b-
hydroxysteroid dehydrogenase type II (11b-HSDII). This leaves only a few cell types 
where GCs are able to activate both the GR and MR under physiological conditions, 
and the only one relevant in the context of EAE and MS is the macrophage. Binding 
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of GCs to the two different receptors enforces macrophage differentiation into 
opposing directions: MR-deficient macrophages are polarized towards the anti-
inflammatory M2 phenotype whereas macrophages lacking the GR adopt a pro-
inflammatory M1 phenotype (Kleiman et al., 2012; Usher et al., 2010). This could 
potentially have implications for the control of EAE and MS by GCs. Finally, many 
synthetic GCs were chemically modified to reduce their affinity to the MR since GCs 
applied at high concentration can overcome the protective effect of 11b-HSDII and 
therefore induce side-effects such as hypertension via the MR in tissues such as 
kidney and heart.  
 
Fig. 3 GC effects on molecular level. GCs are bound by GR (1), Heat shock proteins are released 
(2), the GR can translocate to the nucleus and act as a dimer by directly binding to Glucocorticoid 
responsive elements (3) or as a monomer in complex with other transcription factors. Modified from 
(Herold et al., 2006). 
 
Besides modulating gene transcription, GCs are also known to exert non-genomic 
effects. These mechanisms possibly include direct intercalation of GCs into the cell 
membrane and interaction with a not yet fully characterized membrane GR 
(Bartholome et al., 2004). Alternatively, the ligand-bound GR can exert its function 
within the cytosol rather than the nucleus by interfering with a variety of signalling 
cascades. Examples include decreased recruitment of Lck and Fyn to the TCR 
complex after GC treatment (Löwenberg et al., 2005), direct interaction of the 
cytosolic GR with PI3K (Hafezi-Moghadam et al., 2002) and increased 
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phosphorylation of focal adhesion kinase (FAK) after application of GCs 
(Koukouritaki et al., 1999). In contrast to transcriptional regulation the 
aforementioned effects are generally rapid and may therefore establish a first line of 
immunosuppression that is followed by more long-lasting effects on the level of gene 
expression.  
 
1.6. Metabolic regulation of T cell activation 
Besides steroid hormones there are several other hormones that impact on immune 
cells. Insulin is also an important regulator of several crucial body functions and 
exerts its function through binding to the insulin receptor (InsR). Dysfunctions of 
insulin responsiveness lead to severe consequences like Type 1 or Type 2 Diabetes 
Mellitus (T1DM/T2DM). The first one is caused by autoreactive T cells destroying the 
insulin producing beta cells in the pancreatic islets leading to insulin deficiency. The 
latter one is associated with long-time obesity and an increasing socioeconomic 
problem in the western world. Central to both diseases is disturbed glucose 
metabolism that impacts not only on the cardiovascular system of the patient but also 
impaired clearance of infections (Graves and Kayal, 2008; Müller et al., 2005). There 
has been a long-term debate which population of immune cells is responsible for this 
phenotype. It is known that persistent imbalance between energy uptake and 
expenditure as in obesity generally leads to cellular dysfunctions (Odegaard and 
Chawla, 2013). The InsR is needed for insulin mediated metabolic changes and 
screening for its expression patters revealed that amongst all immune cells only 
lymphocytes are capable of the de novo synthesis of the InsR, so it is reasonable, 
that these cells might be affected by insulin deficiency (Viardot et al., 2007). 
Intriguingly, the lymphocytes show no constitutive expression of the InsR but rather 
activation-induced expression.  
As described above, activation is accompanied by profound morphological changes 
and cytoskeletal rearrangements. It is reasonable, that these alterations are energy 
consuming. Small resting T cells have to differentiate into effector T cells that are 
crawling, proliferating and cytokine secreting. Following activation T cells develop 
into different functional subsets depending on the conditions and the cytokine milieu 
during activation. These programming or fate decision determines the nature of the 
immune response (O'Shea and Paul, 2010; Zhou et al., 2009). A lack of energy in 
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this process could lead to impairment in this phase, which might impact on the 
efficient generation of immune cell subsets. It is known, that metabolic phenotypes 
integrate with T cell function (Gerriets and Rathmell, 2012), so this would be another 
explanation of the insufficient pathogen clearance in diabetes patients. 
T cell metabolism is highly dynamic. Under normal conditions, oxidative 
phosphorylation is the source of energy, as in most healthy cells and the metabolic 
status is intracellular sensed by the ATP to ADP ratio. This system works in normal 
homeostatic proliferation and survival, but during activation the cells have to respond 
quickly to the higher energy demand. The T cells rapidly up-regulate glucose uptake 
and glycolysis as energy source (Fox et al., 2005; Frauwirth et al., 2002; Maciver et 
al., 2008). Activation is induced through two signals (see above). The co-stimulatory 
signal via CD28 leads to increased glucose uptake and is likely to provide part of the 
needed energy. Indeed is the increase in glucose uptake and glycolysis after T cell 
activation dependent on co-stimulation (Jacobs et al., 2008). In line with this, 
reduction of glucose uptake interferes with activation (Jones and Thompson, 2007; 
Vander Heiden et al., 2001). Additionally, T cell activation and proliferation have to be 
tightly regulated. Effector cells have to provide protection against cytokines while 
avoiding massive proliferation and autoimmunity. Direct interference with T cell 
metabolism impacts on immune responses: transgenic overexpression of glucose 
transporter Glut1 leads to increased T cell proliferation, survival and cytokine 
production in mice (Jacobs et al., 2008; Michalek et al., 2011). This also impacts on 
the T cell’s architecture as the cells increase in size. Animals develop 
lymphadenopathy and a mild inflammatory disorder. Corresponding to these findings, 
an impairment of effector T cells to upregulate glucose metabolism leads to 
insufficient cytokine production and proliferation and activation are suppressed, 
which can lead to apoptosis (Alves et al., 2006; Coloff et al., 2011; Coloff et al., 2011; 
Greiner et al., 1994).  
Modulation of the differentiation to Th cell subsets provides another potential 
explanation for increased infection risk in diabetes patients. It is known, that T cell 
metabolism interferes with T cell differentiation (Gerriets and Rathmell, 2012). 
There is also evidence that insulin impacts on effector T cell metabolism: 
radioactively labelled insulin is bound by activated rather than naïve T cells 
(Helderman and Strom, 1977). The InsR expression is a hallmark of activated 
lymphocytes was discovered over 30 years ago (Helderman et al., 1978; Helderman 
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and Strom, 1978). As co-stimulation is required for the switch from oxidative 
phosphorylation to glycolysis, the effect of the InsR is likely synergistic with CD28 
stimulation. Engagement of both receptors results in phosphatidylinositol 3-kinase 
(PI3K) activity, which generates phosphoinositol trisphosphate (PIP3) that leads to 
the recruitment of Akt to the membrane. Akt is activated by pyrovate dehydrogenase 
kinase 1 (PDK1) (Finlay et al., 2009; Waugh et al., 2009) and induces glycolysis and 




Fig. 4 Comparison of signalling pathways of InsR and TCR/CD28 co-stimulation. InsR (A) and 
TCR/CD28 signalling pathways (B) share components and result in analogous metabolic effects. Both 
pathways utilize the central signalling molecule Akt and induce glycolysis and increased glucose 
transport (Frauwirth and Thompson, 2004). 
Pharmacological inhibition of PI3K impairs upregulation of glycolysis after CD28 
mediated co-stimulation illustrating the central importance of Akt activation (Frauwirth 
and Thompson, 2004). The same molecules are utilized in InsR mediated signalling 
(Fig. 4), supporting the hypothesis of a synergistic function of both pathways. It is 
known, that increased glucose uptake can enhance T cell activation and proliferation 
(Jacobs et al., 2008), so it is likely that additional InsR signalling provides more 
energy for T cell differentiation and proliferation as CD28 signalling alone. Also other 
components of this pathway are known to influence T cell function. PDK1 is elevated 
in chronically activated T cells of asthma patients (Ostroukhova et al., 2012). 
Treatment of T cells isolated from those patients with PDK1 inhibitor dichloroacetate 
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(DCA) prevented inflammatory cytokine production and T cell proliferation 
(Ostroukhova et al., 2012).  
However, there is evidence that the PI3K/Akt pathway is not generally essential for 
the metabolic reprogramming of T cells because deficiency in the catalytic subunits 
of PI3K are dispensable for activation induced T cell proliferation (Fruman et al., 
1999; Okkenhaug et al., 2002). Also it has been found for activated CD8+ T cells that 
Akt signalling is not needed for their proliferation in vitro (Macintyre et al., 2011). 
Nevertheless, CD4+ effector T cells are dependent on glucose and a lack of insulin 
responsiveness would be an explanation for the higher infection risk of diabetes 
patients. This is underlined by the fact, that in vitro activated T cells from T2DM 
patients reflect the glycaemic in vivo status (Stentz and Kitabchi, 2003).  
Taken together it is likely that insulin resistance impacts on lymphocyte function and 
that this is the reason for increased susceptibility of T2DM patients to infections. 
Furthermore, altered T cell differentiation could also be of relevance in T cell 
mediated diseases and understanding of this mechanism could lead to promising 
approaches to influence T cell function in the treatment of such diseases.   
 
1.6.1. Insulin receptor silencing in transgenic rats 
To study the importance of the InsR for proper immune cell functions we took 
advantage of an inducible and reversible gene knockdown system in transgenic rats. 
The knockdown in this model is mediated by RNA interference (RNAi). Expression of 
a small interfering RNA (siRNA) targeting the mRNA of the protein of interest leads to 
double-stranded RNA (dsRNA), which is activating the RNA-induced silencing 
complex (RISC) leading to its degradation. For the InsR knockdown (kd) a inducible 
and reversible system was used (Herold et al., 2008), were the expression of the 
siRNA is regulated by a Doxycycline (Dox) sensitive system (Fig. 5). Besides the 
small hairpin RNA (shRNA) under the control of the H1 promotor, which is processed 
to siRNA, the construct is consistent of a second part expressing eGFP as a 
selection marker and Tet-repressor (TetR) under an ubiquitin C promotor. Under 
physiological conditions, the TetR binds to the Tet operon (TetO) of the H1 promotor 
blocking the shRNA expression. Addition of Doxycycline to the system leads to 
shRNA production by blocking the binding of TetR to TetO. This knockdown induction 
is reversible, as stopping Dox treament leads to the renewed blocking of TetO by the 






Fig. 5 Scheme of the inducible and reversible silencing of the InsR. Under physiological 
conditions eGFP and Tet repressor (TetR) are constitutively expressed (upper panel) under a ubiquitin 
C promotor (Ub-p), separated by a viral linker protein (T2A). TetR binds to the Tet operon (TetO) and 
blocks the H1 promotor. If Doxycycline is added to the system it binds the TetR leading to its release 
from TetO and allowing the transcription of an shRNA targeting the InsR mRNA (lower panel); 
modified from (Herold et al., 2008).  
 
1.7. Objective 
T cells circulate through the body and are influenced by a plethora of molecules such 
as chemokines or hormones. The aim of this project was to determine the impact of 
endocrine regulation of T cell function, namely the influence of insulin and GCs on 
effector T cell function and activation. 
Treatment of neuroinflammatory diseases with GCs is widely used but still is 
unsatisfactory understood. We wanted to analyse the impact of GCs on effector 
T cells. For this we took advantage of in vivo generated CNS-antigen specific effector 
T cells and analysed the impact of GCs on central steps of disease development, 
namely polarized effector T cell morphology, transmigratory capacity and the ability 
to interact with APCs. Identification of crucial mechanisms for the benefit of GC 
action could help to develop a more refined treatment.  
T cell morphology and migratory behaviour are central for the pathogenicity of auto-
reactive cells but also essential for proper pathogen defence. Metabolic modulations 
may have an impact on T cell differentiation and function and might also be the link 
between metabolic disturbances as T1DM or T2DM and immunological impairment of 
the patients. We therefore aimed to analyse the impact of lacking insulin 
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responsiveness on T cell activation and different T cell subset functionality, because 
different T cell subsets as Treg, effector T cells and memory T cells have different 
metabolic patterns and may therefore be differentially regulated and affected by InsR 
inactivation. 
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2. Material and methods 
If not specified otherwise, all places are located in Germany. 
2.1. General equipment 
Table 1 General equipment 
Accu-jet® pro pipette controller  Brand GmbH, Wertheim  
Agarose Gel-electrophoresis system Peqlab Biotechnology, Erlangen 
Arium® 611 laboratory water purification 
system 
Sartorius AG, Göttingen 
BD FACSCanto II BD Biosciences, Heidelberg 
Blotting Chamber TE70 Amersham Biosciences, Freiburg 
Centrifuge 5417R for reaction tubes Eppendorf, Hamburg  
Centrifuge 5804 for FACS tubes  Eppendorf, Hamburg 
Centrifuge multifuge 4 KR for Falcon tubes Heraeus, Hanau 
Centrifuge Sigma 2-5 for 96-well plates SIGMA Laborzentrifugen GmbH, Osterode 
am Harz 
Chemilux Gel Imager  INTAS Science Imaging Instruments GmbH, 
Göttingen 
Counter MicroBeta2 Perkin Elmer, Waltham, USA 
Electrophoresis power supply 301 Amersham Biosciences, Freiburg 
Filter Mate Harvester Perkin Elmer, Waltham, USA 
Freezer Hera freeze -80 °C  Heraeus, Hanau 
Freezer Liebherr Comfort -20 °C  Liebherr-International Deutschland GmbH, 
Biberach an der Riss 
Freezer VIP plus -150 °C SANYO Electric Co., Ltd., Moriguchi, Osaka, 
Japan 
Incubator, HERACell 240 Heraeus, Hanau 
Laminar airflow cabinet, HERASafe Heraeus, Hanau 
LSRII BD Biosciences, Heidelberg 
Micropipettes 2 μl, 20 μl, 200 μl, 1000 μl Gilson, Middleton, Wisconsin, USA 
Microscope Primo Star Zeiss, Jena 
Microwave Sharp 
Neubauer improved haemocytometer Henneberg-Sander GmbH, Giessen-  
Lu tzellinden 
pH-Meter 766 Calimatic Knick Elektronische Messgeräte GmbH & 
Co. KG, Berlin 
RS 225 X-Ray Research System Gulmay Medical Systems, Camberley, 
Surrey, UK 
Spectral confocal & multiphoton system TCS 
SP2 
Leica Microsystems, Wetzlar 
Thermomixer Eppendorf, Hamburg 
Vortex Genie-2 Scientific Industries, Bohemia, New York, 
USA 
7500 Real Time PCR System Applied Biosystems, Foster City, California, 
USA 
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2.2. Consumables 
Table 2 Consumables 
8-well chamber slides LabTek™, Nunc, Roskilde, Denmark 
96-well Optical Reaction Plates Applied Biosystems, Foster City, California, 
USA 
96-well Suspension Culture Plate, U-bottom Greiner bio-one GmbH, Frickenhausen 
96-well Tissue Culture Plate 96-well V- 
bottom 
Sarstedt, Nümbrecht 
96-well Suspension Culture Plate, flat 
bottom 
Greiner bio-one GmbH, Frickenhausen 
96-well Opti-Plate Perkin Elmer, Waltham, USA 
Adhesive Sealing Film Perkin Elmer, Waltham, USA 
BD Micro-FineTM+ U-100 Insulin Syringes, 1 
mL (29G 1⁄2”) 
BD Biosciences, Heidelberg 
Cell culture plates 3.5 cm, 6 cm, 10 cm Sarstedt, Nümbrecht 
Cell strainer 40 μm BD Biosciences, Heidelberg 
Cellstar 12 well flat bottom suspension 
plates 
Greiner Bio-One GmbH, Essen 
Cellstar® pipettes 5 mL, 10 mL, 25 mL Greiner bio-one GmbH, Frickenhausen 
CryoTube™ Vials Nunc, Roskilde, Denmark 
ECL nitrocellulose membrane Amersham Biosciences, Freiburg 
FACS tubes BD Biosciences, Heidelberg 
Falcon tubes 15 mL, 50 mL Greiner bio-one GmbH, Frickenhausen 
Filtropur S 0.2, 0.45 Sarstedt, Nümbrecht 
Optical Adhesive Covers Applied Biosystems, Foster City, California, 
USA 
Needles 24G 1”, 20G 1 1⁄2”, 27G 3⁄4”, 25G 
1”, 20G 2 3⁄4” 
B. Braun Melsungen AG, Melsungen  
 
Pipette tips 10 μl, 200 μl, 1000 μl Greiner bio-one GmbH, Frickenhausen 
Reaction tubes 0.5 mL Sarstedt, Nümbrecht 
Reaction tubes 1.5 mL, 2 mL Greiner bio-one GmbH, Frickenhausen 
Syringes 1 mL Henke Sass Wolf, Tuttlingen 
Syringes 2 mL,5 mL, 10 mL BD Biosciences, Heidelberg 
Syringes 60 mL BD Biosciences, Heidelberg 
Transwell system, 3 µm pore size Corning Life Sciences, Acton, USA 
GB004 Gel Blotting Paper Whatman, Schleicher & Schuell, Dassel 
 
2.3. Chemicals and buffer additives 
 
Table 3 Chemicals and additives 
3[H]-Thymidine solution, 37 MBq/mL Perkin Elmer, Waltham, USA 
2-β-Mercapto ethanol Invitrogen, Paisley, UK 
Agarose UltraPure Invitrogen, Paisley, UK 
BSA Carl Roth, Karlsruhe 
CaCl2 * 2 H2O Merck, Darmstadt 
Citric acid  Merck, Darmstadt 
Concanavalin A SIGMA-Aldrich, Taufkirchen 
D-Glucose Merck, Darmstadt 
Dex water soluble SIGMA-Aldrich, Taufkirchen 
Dexa-ratiopharm® 100 mg Injektionslo sung Carl Roth, Karlsruhe 
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DMSO Fermentas GmbH, St. Leon-Rot 
DNA ladder 1kb Serva, Heidelberg 
dNTPs (dATPNa4 *3 H2O, dCTPNa4 *3 H2O, 
dGTPNa4 *3 H2O, dTTPNa4 *3 H2O) 
Genaxxon bioscience, Ulm 
Doxycycline hyclate SIGMA-Aldrich, Taufkirchen 
EDTA Carl Roth, Karlsruhe 
EGTA Carl Roth, Karlsruhe 
Ethanol Carl Roth, Karlsruhe 
Ethidium bromide HyClon, Perbio Science, Bonn 
10% Stripped Fetal Calf Serum (FCS) Invitrogen, Paisley, UK 
GIBCO® Penicillin/Streptomycin Merck, Darmstadt 
GeneRuler 1kb DNA ladder Fermentas 
HEPES Merck, Darmstadt 
KCl Merck, Darmstadt 
KH2PO4 Merck, Darmstadt 
Lymphoprep™ Axis-Shield, Oslo, Norway 
NaHCO3 Merck, Darmstadt 
Na2CO3 Merck, Darmstadt 
NaCl Carl Roth, Karlsruhe 
NaN3 Carl Roth, Karlsruhe 
MgCl2 * 6 H2O Merck, Darmstadt 
MgSO4 * 7 H2O Merck, Darmstadt 
Na2HPO4 Merck, Darmstadt 
Na3C6H5O7 Carl Roth, Karlsruhe 
NH4Cl Merck, Darmstadt 
Phenol Red SIGMA-Aldrich, Taufkirchen 
Prestained protein marker New England Biolabs, Ipswich, USA 
Protease Inhibitor cocktail SIGMA-Aldrich, Taufkirchen 
Rotiphorese Gel 30 Carl Roth, Karlsruhe 
TEMED Carl Roth, Karlsruhe 
Tween-20 Carl Roth, Karlsruhe 
Tris Carl Roth, Karlsruhe 
U73122 hydrate (PLC inhibitor) SIGMA-Aldrich, Taufkirchen 






Table 4 Primer for qrt-PCR 
target gene sequence (5’  3’) 
InsR forward: ATGTGAGACGACGGCGGTGC 
reverse: TCCCGGGCACACCTCTCCAG 
β-actin forward: AGCTCCTCCGTCGCCGGTC 
reverse: CCACCATCACACCCTGGTGCCT 
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2.5. Media and solutions 
2.5.1. Standard cell culture 
All media, buffers and solutions were stored at 4 °C. Buffers and solutions were 
autoclaved at 125 °C for 30 min. 
BSS:  
11% BSS I 
11% BSS II 
 
BSS I:  
50 mM Glucose  
4.4 mM KH2PO4 
13.4 mM Na2HPO4 
0.1% Phenol red 
 
BSS II:  
12.65 mM CaCl2 * 2 H2O  
53.6 mM KCl 
1.37 M NaCl 
9.8 mM MgCl2 * 6 H2O 
8.1 mM MgSO4 * 7 H2O 
 
Coating Buffer: 
45.3 mM NaHCO3  
18.2 mM Na2CO3 
 
GIBCO® DMEM+GlutaMAX™-I, Invitrogen, Paisley, UK  
 
GIBCO® RPMI 1640+GlutaMAX™-I, Invitrogen, Paisley, UK  
 
RPMI ++: 
+ 10% FCS 
+ 1% Penicillin/Streptomycin  
 
DMEM++: 
 +10% FCS 
 +1% Penicillin/Streptomycin 
 
DMEM ReStim:  
DMEM++ 
 +20% ConA-Supernatant 
 +10 ng/mL mouse IL-2 (Peprotech) 
 
PBS (pH 7.4):   
137 mM NaCl  
2.7 mM KCl 
10 μM Na2HPO4  
2.0 mM KH2PO4  
Transmigration medium: 
 RPMI  
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 + 0.5% fat-free BSA 
 
2.5.2. Effector T cell culture 
EH-Medium: 
 DMEM 




 + 1% Penicillin/Streptomycin 
 + 1% rat serum 




 + 10% ConA supernatant 
 + 1% Penicillin/Streptomycin 
 + 5% FCS 
 
2.5.3. MACS® cell seperation 
MACS running buffer:  
PBS pH 7.2  
+ 2.0 mM EDTA  
+ 0.5% BSA  
 
MACS rinsing buffer:  
PBS pH 7.2  
+ 2.0 mM EDTA 
 
2.5.4. Flow cytometry 
OptiLyse® B Lysing Solution, Beckman Coulter, Krefeld 
Alsevers: 
27 mM NaCl 
125 mM D-Glucose  
3 mM citric acid 
30 mM Na3C6H5O7 
 
Annexin binding buffer: 
10 mM HEPES/NaOH, pH 7.4 
140 mM NaCl 
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Krebs-Ringer solution: 
 10 mM HEPES, pH 7.0 
 140 mM NaCl 
 4 mM KCl 
 1 mM MgCl2 
 10 mM glucose 
 
TAC buffer: 
20.0 mM Tris/HCl pH 7.2  
155 mM NH4Cl  
 
FACS buffer:  
PBS pH 7.2  
+ 0.1% BSA  
+ 0.01% NaN3  
 
2.5.5. Protein analysis 
Upper Buffer (stacking gel):  
0.5 M Tris/HCl, pH 6.8 
14 mM SDS 
 
Lower Buffer (separating gel): 
1.5 M Tris/HCl, pH 6.8 
14 mM SDS 
 
Laemmli 1 
62.50 mM Tris/HCl, pH 6.8  
2.0% SDS 
20.0% Glycerol 
5.0% β-mercapto ethanol 
0.025 % Bromphenol 0.5% 
 
SDS Running buffer, 10 
25.0 mM Tris 
192 mM Glycin 




0.1% Tween 20 
 
RIPA (1) 
5.00 mM EDTA 
10.0 mM Tris 
50 mM NaCl 
10.0 mM NaF 
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Lysis buffer (for 1 mL, freshly prepared for each experiment) 
500 µL 2  RIPA 
100 µL NP40 (10%) 
20 µL NA3VO4
 (50 mM) 
1 µL Na2MoO4 (10 mM) 
25 µL protease inhibitor 
354 µL aqua dest. 
 
Blotting buffer, 10  
0.4 M Glycin  
0.5 M Tris 
13 mM SDS 
15 mM NaN3 
 
Blocking Buffer:  
PBS/Tween 
 +5% BSA 
 
Staining solution A  
0.100 M Tris/HCl, pH 8.6 
0.025% Luminol 
 
Staining solution B  
0.11% Para Hydroxy Coumarin acid in DMSO 
 
Development solution  
2 mL Staining Solution A 
0.2 mL Staining Solution B 
1.2 µL H2O2 
  
 
2.6. Antibodies and Reagents 
2.6.1. Flow cytometry: antibodies and dyes 
 
AnnexinV-Cy5, BD Biosciences, Heidelberg 
7-AAD, BD Biosciences, Heidelberg 
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Table 5 Antibodies for flow cytometry 
























CD8β 341 1:1000 fitc 




CD45 Ox1 1:3000 Alexa-647 
CD45RA Ox33 1:2000 PE 
CD62L (LECAM-1) HRL1 1:1000 bio 
CD134 Ox40 1:500 Alexa-647 






Thy1 Ox7 1:500 PerCp 
    
Secondary 
antibody 
SA 1:1000 APC-Cy7 
Intracellular 
proteins: 
   
FoxP3  1:500 PE 
IL-17  1:500 PE 
IFNγ  1:500 PE 
 
FACS antibodies were purchased from BD Biosciences, eBioscience or BioLegend. 
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2.6.2. MACS® technology microbeads 
Table 6 MACS
®







MACS beads were purchased from Miltenyi Biotec, Bergisch Gladbach. For 1  107 
lymphocytes 20 µL beads were used. 
2.6.3. Western Blot antibodies 
primary antibodies:  
Akt: anti-Akt rabbit polyclonal antibody, Cell Signaling Technology, Cambridge, UK 
P-Akt: Phospho-Akt (Ser473) (D9E) XP™ rabbit monoclonal antibody, Cell Signaling 
Technology, Cambridge, UK 
βTubulin: anti-βTubulin mouse polyclonal antibody, Santa Cruz Biotechnology, 
Heidelberg 
ERK: ERK-1 (C-16) rabbit polyclonal antibody, Santa Cruz Biotechnology, 
Heidelberg 
P-ERM: Phospho-Ezrin (Thr567)/Radixin(Thr654)/Moesin(Thr588) rabbit polyclonal 
antibody, Cell Signaling Technology, Cambridge, UK  
Insulin receptor: insulin Rβ (C-19), rabbit polyclonal antibody, Santa Cruz 
Biotechnology, Heidelberg 
All primary antibodies were used in a 1:1000 dilution in PBS/Tween supplemented 
with 5% BSA and 0.01% NaN3.  
 
secondary antibodies: 
Goat Anti Rabbit IgG horseradish peroxidase conjugate, ImmunoPure, Rockford, 
USA 
Goat Anti Mouse IgG horseradish peroxidase conjugate, ImmunoPure, Rockford, 
USA 
The secondary antibodies were utilized in a 1:10000 dilution in PBS/Tween. 
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2.6.4. Reagents for T cell stimulation  
Coating Antibody: Anti Mouse Ig Sheep polyclonal antibody, Roche, Basel, 
Switzerland  
Stimulation:  
JJ319 - Anti Rat CD28 Mouse monoclonal antibody, kindly provided by Prof. Hünig, 
Institute for Virology and Immunobiology, University of Würzburg  
JJ316 - Anti Rat CD28 Mouse monoclonal antibody, superagonist, kindly provided by 
Prof. Hünig, Institute for Virology and Immunobiology, University of Würzburg 
R37 - Anti Rat TCR Mouse monoclonal antibody, kindly provided by Prof. Hünig, 
Institute for Virology and Immunobiology, University of Würzburg  
 
2.7. Enzymes and Kits 
Power SYBR® green, Applied Biosystems, Foster City, California, USA 
Taq-CR Master Mix Kit, Qiagen, Hilden 
Proteinase K, Promega, Fitchburg, USA 
iScript™ cDNA synthesis kit, BioRad, Munich 
eBioscience IC staining: Fixation/Permeabilization concentrate and diluent, 10  
Permeabilization buffer, eBioscience, San Diego, California, USA 
BD Cytofix/Cytoperm™ Kit, BD Biosciences, Heidelberg 
DyLight® 649 microscale antibody labeling kit, Thermo Scientific, Waltham, 
Massachusetts, USA 
2.8. Blood Glucose 
Ascensia Blood Glucose Meter CONTOUR®, Bayer HealthCare AG, Leverkusen  
 
CONTOUR® Test Strips, Bayer, Bayer HealthCare AG, Leverkusen  
 
2.9. Anaesthesia  
2.9.1. Injection:  
Ketamine 10% (Ketavet) 
Xylazine 2%  (Rompun) 
A mixture of 250 µL Ketavet and 50 µL Rompun was prepared immediately before 
the induction of anaesthesia by i.p. injection of 100 µL/100 g bodyweight of the rat. 
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2.9.2. Inhalation 
For temporary anaesthesia, the rats were supplied with an evaporator delivering 4% 
sevoflurane® in a 5% oxygen atmosphere. 
2.10. Software 
Adobe® Illustrator® Adobe Systems, San José, USA 
BD FACS Diva™ software version 6.1.2, BD Biosciences, Heidelberg 
Endnote X, Thomson Reuters, New York City, USA  
FlowJo version 8.8.6, Tree Star, Inc., Ashland, Oregon, USA 
GelPro analyzer, Media Cybernetics, Rockville, USA 
Leica Confocal Software, Leica, Wetzlar 
Prism for Macintosh version 4.0c, GraphPad Software, Inc., San Diego, California, 
USA  
7500 System SDS Software version 1.4.0.25, Applied Biosystems, Foster City, 
California, USA  
2.11. Animals  
The rats used during this project were all Lewis background and bred in the animal 
facility of the University of Göttingen Medical School. All experiments were conducted 
according to the Lower Saxony state regulations and approved by the responsible 
authorities (Niedersächsisches Landesamt für Lebensmittelsicherheit und 
Verbraucherschutz). They were kept under specific pathogen-free conditions in a 12 
hour light-dark cycle. 
Lewis: wt Lewis rats were obtained from Charles River or bread in our own facilities. 
UGC: Lewis rats transgenic for eGFP generated using a lentviral approach. eGFP is 
expressed under the control of an ubiquitin promotor, leading to eGFP expression in 
all tissues (van den Brandt et al., 2004).  
InsR04: Lewis rats transgenic for a lentiviral vector system (FH1tUTG) consisting of 
one cassette coding for the shRNA under a H1 promotor and the control of TetO and 
a second cassette consisting of TetR and eGFP separated by a linker (see Fig. 5; 
Herold et al., 2008).  
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2.12. Animal experiments 
2.12.1. Induction of Experimental Autoimmune Encephalomyelitis (EAE) 
For active EAE, immunization of Lewis rats with the CNS antigen myelin basic 
protein derived from guinea pigs (gpMBP) was carried out under Sevoflurane or 
Ketamine/Xylazine anaesthesia.  
A paste composed of gpMBP (2 mg/mL) emulsified in CFA (2 mg/mL) at a 1:1 ratio 
was prepared. Each animal was injected subcutaneously slightly above the footpad 
of either hind limb with 50 µL paste per side. 
Adoptive transfer EAE (AT-EAE) was induced by i.v. injection of 2 - 10  106 freshly 
restimulated effector T cells.  
The animals were weighed daily and inspected for EAE symptoms. EAE severity was 
assessed according to a 10-grade scoring scale as follows: 0 = healthy; 1 = reduced 
tonus of the tail; 2 = limp tail; 3 = absent righting; 4 = gait ataxia; 5 = mild paresis of 
hind limbs; 6 = moderate paraparesis; 7 = severe paraparesis or paraplegia; 8 = 
tetraperesis; 9 = moribund; 10 = death (Linker et al., 2008). The animals were 
sacrificed according to the animal welfare law at a score of >7. 
2.12.2. In vivo knockdown induction 
The inducible and reversible silencing of the InsR was possible through induced 
expression of an shRNA targeting the corresponding mRNA. shRNA-expression was 
started after blocking of the constitutively expressed Tet-repressor (see 1.6.1) with 
Doxycycline (Dox).  
To obtain a sufficient knockdown efficacy, the shRNA expression was induced 5 days 
prior to T cell isolation in vivo. To this end the animals were fed with Dox containing 
diet ad libitum. To maintain the knockdown during all in vitro experiments, Dox was 
also added to the respective culture medium at a concentration of 2 µg/mL. 
2.12.3. Blood glucose measurement 
For the determination of the blood glucose levels a drop of blood was gained by 
punctuation of the tail vein at the tail tip of the rats with a hollow needle. Glucose 
levels were determined with the Ascendia Blood Glucose Meter and the 
corresponding test strips.  
2.12.4. Generation of encephalitogenic T cells 
The animals were immunized according to the EAE protocol (see 2.12.1). After 
10 days, before the T cells leave the lymph nodes and invade the CNS, the draining 
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popliteal lymphnodes were dissected and passed through a 40 µm nylon mesh. The 
cell suspension was washed once at 300 × g for 10 minutes using RatReMed 
medium and taken into culture in presence of their cognate antigen gpMBP. After 
3 days, the stimulated T cells were purified with a cold gradient (see 2.13.5). 
siGR effector T cells have been generated previously (Tischner et al., 2009). Effector 
T cells were generated as described above and stabely transfected with a lentivirus 
encoding eGFP and a short hairpin RNA (Tischner et al., 2009). Two shRNA 
sequences targeting the rat GR were cloned into the lentiviral vector MSCV-LMP and 
effector T cells were transfected. Pure cell lines (>95%) had been generated that 
have been reported to express strongly reduced levels of the GR and lack GC 
responsiveness. Two cell lines were generated, siGR-A and siGR-B; in all 
experiments conducted for this thesis siGR-A cells have been used. 
2.12.5. Adoptive transfer (AT-) EAE  
AT-EAE was induced in rats on Lewis background by injection of syngeneic 
encephalitogenic T cells. To this end, freshly restimulated encephalitogenic T cells 
were used, that were harvested after 3 days of restimulation (see 2.13.4) and purified 
with a cold gradient. 1-9  106 effector T cells were resuspended in 250 µl sterile 
PBS and injected in the tail vein of manually immobilized recipient rats.  
2.12.6. In vivo expansion of regulatory T cells 
To isolate regulatory T cells in sufficient numbers, these cells were expanded in vivo. 
To this end the antibody JJ316 was utilised. This monoclonal antibody against CD28 
is superagonistic and reported to induce the expansion of regulatory T cells in vivo 
(Lin and Hünig, 2003). To expand regulatory T cells in wt and InsR kd rats, 1 mg of 
the antibody JJ316 was injected intravenously 3 days prior to the lymphocyte 
isolation. 
2.12.7. Generation of bone marrow chimeric rats 
Recipient wildtype Lewis rats were irradiated sublethally (12.5 Gy) and 24 h later 
injected with 1  107 bone marrow cells isolated from eGFP transgenic wt or InsR kd 
rats, respectively. To isolate the bone marrow, the femurs of either hind limb of the 
donor was dissected and transferred into sterile ice-cold PBS. Under sterile 
conditions, the bones were opened with a scissor on both ends and the bone marrow 
was flushed out with a syringe containing 20 mL of ice-cold PBS. The cell suspension 
was passed through a 40 µm nylon mesh and washed (300  g, 5 min). The cells 
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were resuspended in PBS and the cell concentration was determined using a 
Neubauer haematocytometer and adjusted to a cell concentration of 4  107 cells/mL. 
250 µL of this suspension was injected into the tail vein of manually immobilized 
recipient rats. Reconstitution was checked by serial FACS analyses every second 
week.   
2.12.8. Production of rat serum for cell culture 
Male and female rats at the age of 4-8 weeks were sacrificed in carbondioxyde 
atmosphere and the blood was gained by heart puncture with a 10 mL syringe. The 
fresh blood was incubated in 15 mL tubes for 30 min at room temperature (RT) and 
centrifuged at 10000  g for 20 min. The serum was carefully transferred in a fresh 
15 mL tube and inactivated for 60 min at 56 °C. Afterwards, the serum was stored at 
-20 °C.  
2.13. Cellular methods 
2.13.1. Lymphocyte isolation 
Wildtype or InsR kd rats were sacrificed in a carbon dioxide atmosphere. The 
cervical, axial, mesenterial and inguinal lymph nodes were isolated and passed 
through a 40 µm nylon mesh with ice-cold PBS/BSA or RPMI++ using a syringe plug. 
The cell suspension was centrifuged (300 × g for 7 min) and the pellet was 
resuspended in medium or buffer. The cell concentration was determined using a 
Neubauer haemocytometer. 
For splenocyte isolation, the spleen was dissected and passed through a 100 µm 
nylon mesh with PBS. The cells were pelleted at 300  g for 5 min and resuspended 
in 2 mL PBS. 12 mL TAC solution were added followed by 12 min incubation at RT in 
the dark. Subsequently, 16 mL PBS/BSA or medium were added, the sample was 
centrifuged (300 × g for 7 min) and the pellet was resuspended in medium or buffer. 
2.13.2. T cell isolation using MACS® technology 
In case of CD4+ T cell isolation a positive selection using anti-CD4-beads was 
performed according to the manufacturer’s instructions. In brief, 20 µl beads per 1 × 
107 lymphocytes in MACS running buffer were added. After 20 minutes of incubation, 
the cells were washed and the pellet passed through a pre-seperation filter. T cells 
were isolated with the autoMACS device using the possel protocol. 
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For the isolation of regulatory T cells a two-step protocol was utilized. In the first step, 
CD8+ T cells, γδ T cells and B cells were depleted using the respective beads at a 
concentration of 20 µl beads per 1 × 107 lymphocytes and the autoMACS protocol 
deplete. Afterwards the remaining T cells were incubated with 5 µl biotinylated anti-
CD25-antibody for 20 minutes, washed and then incubated with 50 µl streptavidin-
beads. The second separation was performed with the possels protocol of the 
autoMACS. With this protocol, two populations were obtained: CD4+CD25- and 
CD4+CD25+ T cells. The latter population served as regulatory T cells, the CD25 
negative population was used as control cells.  
2.13.3. T cell stimulation 
CD4+ T cells purified by MACS® technology (see above) were stimulated with the 
combination of anti-TCR (R73) and anti-CD28 (JJ319) antibodies. R73 was bound to 
the bottom of each well, JJ319 was added to the culture medium.  
24-well cell culture plates were incubated over night at 4 °C with the coating antibody 
(sheep-anti-mouse-Ig, 2.6 µg/mL) in 0.5 mL coating buffer. After that, the plates were 
washed once with 0.5 mL BSS and twice with 0.5 mL PBS, followed by a 2 h 
incubation with the stimulating anti-TCR antibody at a concentration of 2 µg per well 
in 0.5 mL PBS/BSA. Afterwards, the wells were washed twice with 0.5 mL PBS and 
the T cells were added in 1 mL RPMI++ medium supplemented with anti-CD28 (2 
µg/mL) at a concentration of 1 × 106 cells/mL. FACS analysis, RNA or protein 
isolation was performed 24, 48 and 72 h later. 
In case of stimulation with the superagonistic anti-CD28 antibody JJ316 the plates 
were not coated and JJ316 was added to the culture medium RPMI++ at a 
concentration of 5 µg/mL. ConA stimulation was conducted with 2.5 µg/mL ConA in 
RPMI++. In both cases 1  106 T cells per 1 mL medium were cultured.  
2.13.4. Effector T cell culture 
Encephalitogenic T cells (effector T cells) were cultured in a 3 day/3 day cycle. In the 
first phase, the cells were restimulated with gpMBP in presence of APCs (d3 cells 
after harvesting), whereas they are expanded in the second phase (d6 cells).  
Restimulation: 3 × 106 effector T cells were cultured in 10 mL RatReMed 
complemented with 10 µg/mL gpMBP together with 1.5 × 108 irradiated splenocytes 
(30 Gy) serving as APCs. After two days, 3 mL TCGF medium were added to each 
culture plate. On day three, the stimulated effector T cells were purified using a cold 
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gradient (see below). These cells were used for all in vitro experiments and for 
injection.  
Expansion: 1 × 107 effector T cells were cultured in 10 mL TGCF medium for three 
days, with feeding of the cells with 3 mL fresh TCGF on day two.  
2.13.5. Cold Gradient to isolate effector T cells after restimulation 
The effector T cell culture plates were harvested and rinsed with EH medium. The 
suspension was washed at 300 × g for 10 minutes and the pellet was resuspended in 
5 mL lymphoprep™. The suspension was covered with 2 mL EH medium and 
centrifuged at 1700 × g with reduced acceleration and without brakes for 25 min. 
Afterwards, the interphase was harvested and washed with EH medium at 400 × g 
for 10 min.  
2.13.6. Freezing and thawing of effector T cells 
In order to store effector T cells for longer periods of time the cells were frozen. To 
this end, effector T cells were pelleted and the supernatant was thoroughly removed. 
The cells were resuspended in freezing medium consisting of 50% RPMI and 50% 
FCS. 900 µL of the suspension containing 0.5 – 1.5  107 effector T cells was 
transferred in cryo tubes containing 100 µL DMSO and frozen immediately. 
The cells were thawed in a 37 °C water bath and 10 mL EH-medium were added 
quickly to dilute the DMSO. Subsequently, the cells were pelleted at 300  g for 
7 minutes and resuspended in the appropriate medium (RatReMed for d6 and TCGF 
medium for d3 cells). 
2.13.7. Effector T cell transfer and Dex treatment in vivo 
To study the effects of GCs on effector T cells in vivo, 8  106 to 1  107 eGFP 
expressing effector T cells were transferred into the tail vein of syngenic recipient rats 
and allowed to equilibrate for 48 hrs. Subsequently, the rats were treated with Dex 
intravenously at a dose of 20 mg/kg. Peripheral blood samples for the analysis of 
lymphocyte counts were obtained by repeated bleedings (50 µL each) from the tail 
vein, added to 5 mL Alsevers and analyzed by flow cytometry. This allowed 
determination the total amount of eGFP+ cells present in a defined volume of blood.  
2.13.8. Flow cytometry 
For standard stainings lymphocytes were labelled with flourochrome-conjugated 
antibodies targeting extracellular surface markers or intracellular cytokines or 
material & methods 
 33 
transcription factors. For the latter ones, special intracellular staining protocols had to 
be performed after extracellular staining. 
 
Extracellular staining:  
8  105 lymphocytes were used for each staining. Flourochrome- or biotin-conjugated 
antibodies were added in titrated concentrations. After 20 min at 4 °C, the samples 
were washed with 4 mL FACS buffer at 400  g for 5 min. If a biotinylated antibody 
was used in the first step, a second step was conducted using a streptavidin-
conjugated flourochrome. The samples were analysed using a FACSCanto II device.  
 
Intracellular staining: 
1  106 lymphocytes were stained for surface markers as described above and the 
supernatant was removed thoroughly. Afterwards, the cells were fixed and incubated 
with antibodies against intracellular molecules. Two different protocols were used. 
BD protocol (for cytosolic proteins) 
The cells were thoroughly resuspended in 250 µL Fixation/Permeabilization solution 
for 20 min at 4 °C. Afterwards, the cells were washed two times with 1 mL BD 
Perm/Wash™ buffer and resuspended in 50 µL BD Perm/Wash™ buffer. The 
antibody was added in an appropriate concentration (see table 5) and incubated at 
4 °C for 30 min, followed by washing of the cells twice with 1 mL BD Perm/Wash™ 
buffer. The pellet was suspended in 50 µL FACS buffer and analysed using a 
FACSCanto II device. 
 
eBioscience protocol (for transcription factors) 
The cellular pellet was resuspended in 100 µL freshly prepared Fix/Perm buffer 
(25 µL concentrate + 75 µL diluent) and incubated for a minimum of 30 min at 4 °C. 
Afterwards, the cells were washed twice with 2 mL 1  Perm buffer (10  Perm buffer 
diluted in aqua dest.) at 350  g for 7 min. The fluorescently labelled antibody was 
added at a proper concentration (see table 5) and the cells were incubated for 30 min 
at 4 °C. Then the cells were again washed twice with 2 mL Perm buffer, resuspended 
in the remaining buffer and subsequently analysed by flow cytometry using a 
FACSCanto II device. 
 
Apoptosis analysis: 
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1  106 lymphocytes were stained for surface markers as described above. 
Afterwards, each sample was resuspended in 100 µL AnnexinV binding buffer 
complemented with 3 µL 7-AAD and 1 µL AnnexinV-Cy5 and incubated for 15 min. 
Afterward, the samples were directly analysed with a FACSCanto II device without a 
further washing step. 
 
FACS analysis of blood samples 
Blood was obtained through bleedings of the tail vein (ca 40-50 µl) and directly 
dropped into FACS tubes filled with alsevers. The samples were centrifuged at 400  
g for 5 min and extracellular staining was performed. Afterwards, the cells were re-
suspended in 100 µL OptiLyse® and incubated for 12 min at RT. Then 1 mL of ice-
cold water was added and the samples were incubated for at least 1.5 h at RT. 
Before FACS analyses they were washed with 3 mL FACS buffer (400  g, 5 min). 
2.13.9. Apoptosis induction 
Apoptosis was induced by three different stimuli. (i) T cells were cultured under 
serum-starved conditions (media containing 1% or 0% FCR, respectively); (ii) T cells 
were cultured with different concentrations of GC (10-6, 10-7, 10-8 and 10-9 M Dex); 
(iii) T cells were irradiated at different doses (0.5 - 5 Gy). For all stimuli 1  106 T cells 
were cultured in 1 mL RPMI++. Apoptosis rate was determined as described under 
2.13.8. 
2.13.10. 3H-thymidine suppression assay 
In vivo expanded regulatory T cells (see 2.12.6.) were isolated via MACS® 
technology (described in 2.13.2). Irradiated splenocytes served as APCs and CD4+ T 
cells stimulated with ConA as target cells. The latter ones were generated by positive 
MACS® selection as described above. For APCs, the splenocytes of a naïve wt rats 
were isolated as described in 2.13.1 and irradiated for 6 min at a dose rate of 5 
Gy/min (total dose 30 Gy). 1  105 APCs were mixed with 0.5  105 target cells in 200 
µL RPMI++ supplemented with 2.5 µg/mL ConA. Subsequently, regulatory T cells 
were added at three different effector:target ratios: 1:1, 1:5 and 1:25. All samples 
were run in triplicates. After 2 days, 100 µL of the supernatant were exchanged with 
100 µL medium containing 1 µL 3H-thymidine stock. After additional 16 h the wells 
were harvested to Filtropur fibreglass filters. After drying at RT, MeltiLex scintillator 
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film was melted onto the filters in a microwave followed by analysis in a β-plate liquid 
scintillation counter (Perkin Elmer).  
2.13.11. 51Cr release assay 
The 51Cr release assay was used to determine the function of cytotoxic T 
lymphocytes (CTLs), which are capable of lysing MHC mismatched target cells. The 
latter ones were labelled radioactively with 51Cr. After lysis, the isotope is released to 
the medium and can be detected in the supernatant. The relative lysis is calculated 
by dividing the released radioactivity by the residual radioactivity in the cell pellet. 
To generate a sufficient number of alloreactive cytotoxic T lymphocytes (CTLs), wt 
and InsR kd rats were immunized with allogenic splenocytes isolated from DA rats. 
To this end, the whole spleen of the donor rat was dissected and passed through a 
100 µm nylon mesh. The cells were washed once with ice-cold PBS at 300  g for 
7 min at 4 °C. The pellet was resuspended in sterile PBS and the concentration was 
determined using a Neubauer haemocytometer. 1.5  107 cells were injected in a 
volume of 50 µL in either footpad of the recipient’s hind limbs. 5 days later, the 
animals were fed with Dox-containing diet ad libitum to induce the knock down. After 
10 days, the draining popliteal lymphnodes were isolated and the lymphocytes were 
restimulated in a 1:50 ratio with allogenic irradiated splenocytes (dosis 30 Gy) in 
DMEM ReStim. In parallel, lymphocyte blasts (target cells) were produced by 
cultivating splenocytes from DA rats in presence of 2.5 µg/mL ConA and 2 µg/mL 
mouse IL-2. After 5 days, the cells were harvested. The target cells were 
resuspended in 100 µL FCS and labelled with 51Cr at a concentration of 1 µCu/mL. 
Subsequently, the labelled blasts were exposed to the CTLs at different 
effector:target ratios for 4 h. 50 µL supernatant were transferred into a 96 well 
OptiPlate (Perkin Elmer) and 100 µL liquid scintillation cocktail (Perkin Elmer) were 
added. To the residual 150 µL 10 µL Triton X were added and mixed. Subsequently, 
50 µL of the lysed pellet were transferred into a second 96 well plate and 
supplemented with 100 µL scintillator. Both plates were sealed with adhesive covers 
and mixed thoroughly. The specific lysis as indicated by 51Cr release was determined 
by measurement of 51Cr in the supernatant relative to the total amount of radioactivity 
in the lysed pellet. The lysis was calculated as [(CCM supernatant  4)/(CCM pellet  
3 + CCM supernatant)]. The specific lysis is determined as [lysis-spontaneous 
release]. 
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2.13.12. Transmigration of T cells 
To assess the transmigratory behaviour of T cells an in vitro transwell system was 
utilized. Effector T cells were used in this set-up due to their motility and spontaneous 
migration through pores. To this end, 6.5 mm transwell inserts with a 3 µm pre size 
were used. 
Effector T cells were used directly after restimulation and isolation via the cold 
gradient. The cells were treated with either Dex or PBS for 3 h in transmigration 
medium containing 0.5% fat-free BSA, washed with RPMI medium (300  g, 10 min) 
and resuspended in transmigration medium in a concentration of 10  106 cells/mL.  
The lower wells of the transwell system were filled with 600 µL transmigration 
medium and 100 µL of the effector T cell suspension (1  106 cells) was added to the 
upper chamber. The cells were allowed to migrate for 4 h at 37 °C. To calculate the 
relative migration, additional wells containing 500 µL medium and 100 µL cell 
suspension were prepared and set to 100% (input sample). Afterwards, 300 µL of the 
medium in the lower chambers were harvested and the transmigrated T cells were 
counted by addition of 50 µL APC beads (BD bioscience) using a FACSCanto II 
device. The number of cells per bead was calculated relative to the input sample. 
Each sample was run in duplicates.  
2.13.13. Measurement of Ca2+ signalling 
The measurement of intracellular Ca2+ signalling was performed by labelling of 
effector T cells with Indo1, a Ca-sensitive dye shifting its emission spectrum from 475 
nm (Indo blue) to 400 nm (Indo violet) after saturation with Ca2+ ions. This change in 
wave length can be detected by flow cytometry. 
Effector T cells were used after antigen stimulation and purification by cold gradient 
(see 2.13.5). The cell concentration was determined with a Neubauer 
haematocytometer and 1  106 cells were suspended in 700 µL TCGF medium. 
0.015% Pluronic F- 127 and 1 μM Indo-1-AM were added to the cells and incubated 
for 25 min at 30 °C. Afterwards, 700 µL TCGF medium was added and the cells were 
incubated for 10 min at 37 °C. The cells were pelleted for 4 min at 300  g and 
resuspended in 1 mL Krebs-Ringer-solution supplemented with 1 mM Ca2+ and 
washed again for 4 min at 300  g. After resuspending the cells in 500 µL of Krebs-
Ringer solution the Ca2+ signal was measured with a LSR II device (Becton 
Dickinson). After recording a baseline for 25 sec, 5 µL Dex (10-5 M, final 
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concentration 10-7 M) or PBS was applied and the measurement was continued for 
5 min. 
To determine the release of Ca2+ only from intracellular sources, the cells were 
resuspended in 600 µL Krebs-Ringer-solution containing 0.5 M EDTA after the 
incubation with Indo1. After recording of the baseline (25 sec) and the measurement 
of intracellular Ca2+ release after addition of 6 µL Dex (10-5 M, final concentration 
10-7 M) or PBS (4 min), the extracellular Ca2+ was restored by addition of 1 mM CaCl2 
and the Ca-signal was recorded for 2 more minutes. 
2.13.14. Analysis of T cell - APC conjugate formation by FACS 
To measure the capability of effector T cells to interact with APCs, a new approach 
was set up. eGFP positive effector T cells were co-cultivated with flourochrome-
labelled (PerCp) APCs. Subsequent FACS analysis allowed detecting eGFP/PerCp 
double positive events to calculate the percentage of cells that had formed 
conjugates. APCs were derived from freshly isolated rat thymi that were passed 
through a 40 µm nylon mesh. The cells were centrifuged at 300  g for 5 min and 
resuspended in 5 mL RatReMed at a concentration of 1.5 107 cells/mL. The cells 
were pulsed with 10 µg/mL gpMBP for 1 hr at 37 °C. In parallel, freshly restimulated 
eGFP-transgenic effector T cells (see 2.13.4) were incubated with 10-7 M Dex for 10, 
30, 60 or 180 min in RatReMed. Pretreatment with 0.25 µM U73122 was performed 
20 min prior to the addition of Dex. Subsequently, the cells were harvested, washed 
and 5  104 effector T cells were incubated with 2.5  106 APCs for 1 hr at 37 °C, 
followed by staining of the APCs with an anti-Thy1-PerCp antibody and FACS 
analysis. Conjugates were defined as eGFP/PerCp double positive events. 
2.13.15. Confocal microscopy 
To analyze the cell size by confocal microscopy, 1  106 naïve or stimulated T cells 
were harvested, washed with PBS and resuspended in 400 µL Krebs-Ringer solution. 
Cells were analysed in 8-well chamber slides (LabTek™, Nunc) using the Leica TCS 
SP2 microscope (Leica objective PL APO 631.3 Glycerol HCX) and Leica Confocal 
Software. eGFP was excited at 488 nm and emission was collected from 530-600nm. 
Pictures were taken prior to stimulation of the T cells via TCR/CD28 co-stimulation as 
described in 2.13.3 and on day 1, 2 and 3 during stimulation.  
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2.13.16. Production of ConA-Supernatant 
ConA supernatant was used as a medium additive for TCGF medium and DMEM 
ReStim and was produced by stimulation of whole splenocytes with ConA in vitro. To 
this end spleens of three Lewis rats were dissected and passed through a 100 µm 
nylon mesh. The cells were suspended in 200 mL RPMI supplemented with 1 % 
Penicillin/Streptomycin, 1% sodium pyruvate, 0.1 % rat serum, 2.5 µg/mL ConA and 
1.5 µL β-mercapto ethanol and dispensed in 20 mL cell culture dishes. After 28 h the 
cells were harvested into 50 mL Falcon tubes and centrifuged at 3000 rpm and 4 °C 
for 15 min. The supernatant was transferred into fresh Falcon tubes and stored at -20 
°C. For usage the supernatant was thawed and centrifuged again at 4000 rpm and 4 




2.14. Molecular methods 
2.14.1. Polymerase chain reaction (PCR) 
Analysis of gene expression i.e. for genotyping was performed by PCR. The PCR 
reaction mix consisted of 1 µL DNA or cDNA, 0.2 µL Taq polymerase, 0.5 µL primer 
mix (10 mM, forward + reverse), 2.5 µL Mg-buffer (10) and 1 µL dNTPs in 19.8 µL 
aqua dest..  
Table 7 PCR protocol 
step temperature time  
initial denaturation 95 °C 2 min 
denaturation* 95 °C 15 sec 
primer annealing* 60 °C  30 sec 
elongation* 72 °C 30 sec 
final elongation 72 °C 10 min 
* in 35 cycles 
 
 
material & methods 
 39 
2.14.2. RNA isolation 
The Zymo Research RNA isolation kit II was used to isolate RNA according to the 
manufacturer’s instructions. 5  105 cells were used for each sample. 
The cells were harvested and pelleted at 350  g for 7 min. The pellet was lysed 
using 600 µL ZR buffer and transferred to a column placed in an E-cup. The samples 
were centrifuged at Vmax (ca 21000  g) for 1 min and the flow through was 
discarded. The column was washed once with pre-wash buffer (400 µL, 1 min Vmax) 
and twice with wash buffer (700 µL and 400 µL, 1 and 2 min Vmax). Afterwards, the 
column was incubated with 30 µL RNAse/DNAse free water for 1 min at RT, followed 
by elution of the RNA into a fresh E-cup (1 min Vmax). 
 
2.14.3. cDNA synthesis 
cDNA synthesis was performed with the iScript cDNA sythesis kit (BioRad) according 
to the manufacturer’s instructions. For each 20 µL reaction 2 µL of isolated RNA was 
used. In brief, RNA was diluted in aqua dest. to a volume of 14.8 µL. 5 µL iScript 
buffer and 0.2 µL reverse transcriptase was added to each sample, followed by 5 min 
incubation at 25 °C. Afterwards, the samples were incubated at 42 °C for 30 min and 
the rection was stopped thereafter at 85 °C for 5 min. Successful cDNA synthesis 
was checked by PCR using β-actin primer.  
2.14.4. quantitative realtime PCR 
To determine the relative amount of specific mRNA transcripts of a protein of interest, 
quantitative realtime PCR was performed. With this, the double-stranded PCR 
product amount is measured in each cycle by use of the DNA intercalatind dye SYBR 
green. To this end, cDNA obtained from stimulated T cells or effector T cells was 
analysed with InsR primers and primers for the housekeeping gene β-actin. For 1 
sample, 1 µL of template cDNA was mixed with 0.5 µL prediluted primer mix 
(10 mM), 12.5 µL of the Power SYBR Green PCR Master Mix and 11 µL ddH2O. 
After each PCR cycle (see table 8) the amount of double strand DNA was measured 
and calculated by the Applied Biosystems 7500 System SDS Software. Crossing 
threshold (CT) values of the target genes were substracted by the values of the 
housekeeping gene (Δ CT). The quantity was calculated as 2-ΔCT relative to the wt 
control. Statistical analysis was performed using GraphPad Prism.  
 
material & methods 
 40 
Table 8 qrtPCR protocol 
step temperature time  
enzyme activation 50 °C 2 min 
initial denaturation 95 °C 10 min 
denaturation* 95 °C 15 sec 
annealing/elongation* 60 °C  1 min 
dissociation stage 95 °C 15 sec 
 60 °C 20 sec 
recording of the 
dissociation curve 
stepwise rising of the 
temperature to 95°C 
20 sec 
* in 40 cycles 
 
 
2.14.5. SDS PAGE  
The protein expression of cells was analysed by western blot. To this end, the 
proteins were separated by SDS-polyacrylamide gel electrophoresis (PAGE) and 
subsequently transferred onto a nitrocellulose membrane. 
The cells were harvested, washed with PBS and taken up in lysis buffer (40 µL buffer 
for 1  106 cells). After 1.5 h on ice the lysates were centrifuged at 21000  g for 
25 min and the supernatant was carefully transferred into the equal volume of 2 
Laemmli. The lysates were heated at 95 °C for 5 min and separated on a 7.5 % SDS-
PAGE gel.  
For SDS page both separating and stacking gel were freshly prepared according to 
table 9, APS was added shortly before pouring of the gel.  
 
Table 9 SDS-PAGE gel recipe 
ingredients stacking gel separating gel (7,5%) 
upper buffer 938 µL - 
lower buffer - 1.95 mL 
30% acrylamide 600 µL 2.025 mL 
H20 2.205 mL  3.975 mL 
TEMED 3.75 µL 7.5 µL 
APS (added directly prior to casting) 37.5 µL 49,95 µL 
 
material & methods 
 41 
20 µL of the protein lysates (= 2.5 x 105 cells/lane) or 8 µL of prestained protein 
marker were loaded per lane. Empty pockets were filled with 20 µL 1 Laemmli. The 
SDS-PAGE was run at 20 mAmp per gel for 50 min.  
2.14.6. Western Blot 
The proteins separated by SDS-PAGE were further analyzed by Western Blot. To 
this end the proteins were transferred to an ECL nitrocellulose membrane and 
stained with specific antibodies.  
The membrane and filter paper were pre-wetted in 1 blotting buffer. The separating 
gel (see above) was placed on the membrane and between two filter papers in a 
semi-dry blotting chamber. After blotting at 16 V for 1:10 h the gel was discarded and 
the membrane was incubated in blocking buffer for 50 min. Afterwards, the 
membrane was washed three times for 10 min with PBS/Tween and incubated at 
4 °C over night with the primary antibodies, followed by three washing steps for 
10 min in PBS/Tween. The incubation with a HRP-conjugated secondary antibody in 
a 1:10000 dilution in PBS/Tween was performed at room temperature for 1 h. After 
three washing steps the staining was conducted by adding 2 mL freshly prepared 
development solution per membrane and chemiluminescence was detected using the 
ChemiLux Imager. Densitometric quantification of the band intensities was achieved 
using GelPro analyzing software. In case of P-ERM both bands were totalled. The 
specific background was individually substracted in each case.  
2.15. Statistical analysis 
Statistical analysis was performed using Prism software. For all analyses student’s 
unpaired t-test was used. All data is depicted as mean ± s.e.m.. Measures of 








3.1. Influence of GCs on EAE 
GCs are known to suppress T cell functions (Herold et al., 2006; Reichardt et al., 
2001; Wilckens and De Rijk, 1997). They are the treatment of choice for autoimmune 
diseases and high-dose GC therapy is the standard regimen for patients suffering 
from acute MS relapses. The action is quick and effective, but the exact mechanisms 
how GCs exert their beneficial effects are still not fully understood. T cell migration is 
a crucial step during disease progression. Impact of GCs on effector T cell migration 
or morphology would be one possible mechanism explaining the beneficial effects 
during treatment. Therefore we set out to analyse the immediate rapid effects of GCs 
directly on the cellular level using CNS-antigen-specific effector T cells. 
3.1.1. Generation of encephalitogenic T cells for morphological analysis 
Antigen-specific effector T cells are an important pathogenic factor in MS. To study 
the influence of GCs on their morphological features they can be isolated from 
immunized rats and propagated in vitro. As a first approach to obtain insight into their 
morphological changes following treatment, gpMBP-specific encephalitogenic T cells 
(effector T cells) were generated from eGFP transgenic UGC-Lewis rats. Repeated 
restimulation with gpMBP confirmed their antigen specificity as published (Wekerle et 
al., 1986). Analysis of these cells by confocal microscopy was done in collaboration 
with Nora Müller (University of Würzburg). After treatment of the cells with the GC 
Dexamethasone (Dex), a dramatic alteration of T cell morphology was observed, 
which was not seen in the PBS treated controls (Fig 6). Most notably, the polarized 
structure of the effector T cells was lost after incubation with Dex (Fig. 6A). The 
lammelipodiae retracted and the cells adapted a round shaped form. Interestingly, 
this effect was observed as early as 10 min after treatment and lead to a significant 
reduction of the T cell area as depicted in Fig. 6B. The effect was most pronounced 
after 180 min of Dex treatment, when the cell size was reduced by approximately 
half. Since these are remarkable alterations of the T cell cytoskeleton, which is 
important for T cell functions as transmigration or chemotaxis, we further analysed 






3.1.2. The transmigratory capacity of effector T cells is impaired by GC treatment in 
vitro 
Transmigration or extravasation of T cells from blood vessels into target tissues is a 
key event during inflammation. This crucial mechanism is thought to be inhibited by 
GCs through tightening of the blood-brain-barrier (Paul and Bolton, 1995; Romero et 
al., 2003), but also inhibition of the transmigratory capacity of T cells might be an 
important mechanism. The rearrangements of the cytoskeleton observed after GC 
treatment could potentially interfere with transmigration, because the polarized 
structure of T cells is essential for proper migration and extravasation and is needed 
for their activation (Billadeau et al., 2007). To assess the transmigratory behaviour of 
effector T cells, a transwell system was used, where the two compartments are 
separated by a membrane with a 3 µm pore size. Activated T cells spontaneously 
transmigrate through these pores and the transmigrated population can be quantified 
Fig. 6 GC induce effector T 
cell depolarization and 
reduction of T cell size. (A) 
Newly generated effector T cells 
were incubated with 10
-7
 M Dex 
or PBS as a control for the 
indicated periods of time. 
Morphological alterations were 
analysed by staining of the 
cytoskeleton with Phalloidin-
Alexa488 and confocal 
microscopy. Scale bar equals 
10 µm. Quantitative analysis of 
the cell area is depicted in (B). 
Confocal microscopy and 
analysis was performed by Dr. 




by FACS. To assess this property, effector T cells were pre-incubated with 10-7 M 
Dex for 10, 30, 60 and 180 min and thereafter allowed to transmigrate without further 
Dex treatment for 3 h. As a control effector T cells without pretreatment with Dex 
were used. Already 30 min of Dex treatment prior to the transmigration assay 
significantly reduced the number of effector T cells that had crossed the membrane 
(Fig. 7). The percentage of transmigrated effector T cells declined even further over 
time. After 3 h pre-incubation with Dex, the number of transmigrated cells was 
reduced to 50% of the untreated control.  
This is in line with the dynamics of T cell depolarization. We conclude, that GCs 






3.1.3. Dex reduces the capacity of effector T cells to form APC conjunctions  
Altered morphology of effector T cells is likely to influence several functions besides 
transmigration. Another crucial step in the course of an immune response is the 
interaction with professional antigen presenting cells (APCs). The formation of such 
conjugates is essential for the reactivation of the T cells at the site of inflammation. 
To analyse whether the capacity of T cells to interact with APCs is also impaired by 
the morphological changes induced by GC treatment, an experimental set-up was 
designed to quantify the number of conjugates that are formed with APCs. FACS 
analysis was used to determine the kinetics of the GC-induced changes. To track 
effector T cells specifically, we derived them from eGFP transgenic UGC Lewis rats 
by immunization with gpMBP as described earlier. Freshly isolated thymocytes from 
wt Lewis rats were used as APCs, because these cells are also used for the antigen-
Fig. 7 Impaired transmigration of effector 
T cells after GC treatment. After 
preincubation of effector T cells with 10
-7
 M 
Dex or PBS as a control for 10, 30, 60 or 
180 min, respectively a transmigration assay 
was performed without further Dex 
treatment. T cells were allowed to migrate 
through a 3 µm pore size transwell 
membrane for 3 h. The number of cells that 
had migrated into the lower chamber was 
counted by FACS using beads as a 
standard. The cell number in a control setup 
without Dex pretreatment was set to 100%. 
N = 4 (one out of four independent 
experiments is depicted, mean ± SEM 
(Müller et al., 2013) 
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specific restimulation of effector T cells during the course of cultivation. The APCs 
were pulsed with gpMBP for 1 h. In parallel, eGFP-transgenic effector T cells were 
treated with Dex for 10, 30, 60 and 180 min. Subsequently, the effector T cells were 
mixed with the antigen-pulsed thymocytes and allowed to form conjugates for 1 h. 
Afterwards, these cells were stained with an anti-Thy1 antibody to specifically identify 
the thymocytes, because all thymocytes express this marker and as this molecule is 
not involved in the formation of the immunological synapse. To this end, the 
thymocytes were labelled with anti-Thy1-PerCp antibody and the percentage of 
GFP/PerCp double positive events representing conjugates formed by effector T 
cells and APCs was assessed by FACS (Fig. 8).  
 
Fig. 8 FACS plots showing effector T cell-APC conjugate formation. Effector T cells were 
pretreated with 10
-7
 M Dex (0 min; A or 30 min; B) and subsequently allowed to form conjugates with 
PerCp labelled APCs (anti-Thy1-PerCp). The percentage of double positive events representing 
conjugates was determined. Two representative plots out of five independent experiments are 
depicted. 
In each experiment, conjugate formation by untreated effector T cells was set to 
100 %. Interestingly, the capability of effector T cells to form stable interactions with 
APCs was already significantly reduced as early as 10 min of preincubation with 
10-7 M Dex. The percentage of conjugates decreased even further with a longer time 
of pretreatment (Fig. 9). Notably, 30 min of pre-incubation with Dex was sufficient to 
reduce the conjugate formation to 40% compared to untreated effector T cells and 
this effect was maintained for up to 3 h. We conclude, that the GC induced reduction 
of effector T cell-APC interaction could contribute to the beneficial effect of GC 






3.1.4. Dex treatment induces phosphorylation of ERM proteins 
The hitherto obtained results indicated an important link between GC treatment and 
the cytoskeleton. Candidate molecules that might be regulated by GCs are proteins 
of the Ezrin-Radixin-Moesin (ERM) family, two of which are expressed in T cells, 
namely Ezrin and Moesin. These proteins are highly phosphorylated in resting cells 
and thereby provide a link between the membrane and the cytoskeleton. Following T 
cell activation they are dephosphorylated and thereby allow the cytoskeleton to be 
rearranged. This leads to the polarization of the cell, the formation of lamellipodiae at 
the leading edge and the formation of the distal pole complex. To investigate the 
involvement of ERM proteins in the GC-induced cytoskeleton rearrangements, 
effector T cells were treated with 10-7 M Dex or PBS for different periods of time, 
subsequently lysed and analysed by western blot. An anti-P-ERM antibody was used 
that detects phosphorylation at specific threonine residues (Thr567; Ezrin/Thr558; 
Moesin), the predominant protein modifications seen after stimulation (Fig. 10A). 
Following Dex treatment, the ERM proteins were rapidly phosphorylated. 
Phosphorylation was initially detectable as early as 10 min after treatment, reaching 
maximal levels after 30 min of treatment. In contrast, treatment with PBS had no 
influence on P-ERM levels. To obtain a more quantitative picture, the amount of P-
ERM relative to the untreated control was determined by densitometric analysis (Fig. 
10B) based on five experiments in total. This revealed that ERM phosphorylation 
already increased after 10 min of Dex treatment. After 30 min it had increased three-
Fig. 9 GCs reduce the capability of 
effector T cells interact with APCs. 
eGFP-transgenic effector T cells were 
pretreated with 10
-7
 M Dex for 10, 30, 60 
or 180 min, washed and incubated for 1 h 
with MBP-pulsed thymocytes serving as 
APCs. Afterwards, the thymocytes were 
stained with an anti-Thy1-PerCp antibody 
and the formation of conjugates as 
indicated by GFP/PerCp double positive 
events was assessed by FACS. N = 8 
(five independent experiments). Conjugate 
formation without Dex treatment was set 
to 100%. The percentage of conjugates is 




fold compared to the untreated control (Fig. 10B). We conclude, that the observed 
GC-incuced changes of the cytoskeletal architecture of effector T cells could be 





3.1.5. GC induced ERM phosphorylation requires the presence of the GR 
As we had observed, GC treatment induced phosphorylation of ERM proteins in 
effector T cells. To confirm that this mechanism was mediated by the GC receptor 
(GR), siGR effector T cells were used. These cells were generated by retroviral 
transduction of wt effector T cells with short hairpin RNA (shRNA) targeting the rat 
GR. Expression of this shRNA led to the reduction of GR protein levels and the 
absence of GC responsiveness (Tischner et al., 2009). These GR-deficient effector 
T cells were treated with 10-7 M Dex or PBS for 5, 10, 20, 30 and 60 min and 
subsequently analysed by western blot. Importantly, the P-ERM levels in these cells 
did not change after GC treatment (Fig. 11 A and B), indicating that the GR was 
essential for phosphorylation of ERM-proteins. Quantification of the band intensities 
of P-ERM in four independent experiments revealed that no ERM phosphorylation 
occurred in siGR effector T cells following Dex treatment. Of note, this finding is in 
line with the observation that siGR effector T cells do not undergo depolarization and 
cytoskeletal rearrangements after Dex treatment (Müller et al., 2013). We conclude, 
Fig. 10 GCs induce rapid phosphorylation 
of ERM proteins. (A) Western blot analysis 
of effector T cells that were incubated with 
10
-7
 M Dex or PBS as a control for the 
indicated time periods. Lysates were 
analyzed for P-ERM levels; 5  10
5
 cells 
were loaded in each lane. ERK expression 
served as a loading control. One 
representative western blot out of 5 
independent experiments is depicted. (B) 
Densitometric quantification of protein band 
intensities using GelPro analyzing software. 
For P-ERM the totalled density of both 
protein bands was determined. The diagram 
depicts the relative amount of 
phosphorylated ERM as compared to 
untreated cells (mean ± SEM). The 
experiment was independently repeated 5 
times (Müller et al., 2013). 
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that GCs induced both ERM phosphorylation as well as the observed cytoskeletal 
rearrangements could be mediated by the GR.  
 
 
3.1.6. Effector T cell depolarization is not accompanied by increased calcium 
signalling 
Up to now we had identified a new effect of GCs on effector T cells leading to 
cytoskeleton rearrangements and P-ERM phosphorylation. To further dissect this 
mechanism and the pathway leading to the observed changes, the Ca2+ response to 
GC treatment was analysed. 
Ca2+ is an important second messenger that is involved in numerous signalling 
cascades. An increase in cellular Ca2+ levels could also be an effect caused by GCs. 
To measure changes in intracellular Ca2+ levels we made use of the Ca-sensitive dye 
Indo blue. The emission maximum changes from 475 nm (blue) in Ca2+ free medium 
to 400 nm (violet) when bound by Ca2+. By determining the shift in the ratio of Ca-
unbound to Ca-bound indo (blue:violet) by FACS the signalling events can be 
displayed over time. In order to observe changes in the Ca2+ levels, a baseline was 
recorded for 20 sec prior to treatment of the cells with 10-7 M Dex or PBS as control. 
Interestingly, Dex treatment had no influence on the intracellular Ca2+ levels 
compared to PBS treated control cells (Fig. 12 left). 
Fig. 11 GC induced P-ERM 
phosphorylation requires presence 
of the GR (A) Wester blot analysis of 
ERM phosphorylation in siGR effector 
T cells after treatment with 10
-7
 M Dex 
or PBS as a control for the indicated 
time. Equal numbers of cells were 
loaded in each lane; ERK expression 
served as a loading control. One 
representative analysis out of 4 is 
depicted. (B) Densitometric analysis of 
protein band intensities using GelPro 
analyzing software. For P-ERM the 
combined density of both protein 
bands was determined. The diagram 
depicts the relative amount of 
phosphorylated ERM compared to 
untreated cells (mean ± SEM). The 
experiment was independently 





Fig. 12 Dex treatment of effector T cells does not trigger calcium signalling. Effector T cells were 
labelled with the calcium sensitive dye Indo-1. After recording of a baseline for 20 sec, the cells were 
treated with 10
-7
 M Dex or PBS as a control (indicated by an arrow). An increase in the ratio of Indo 
blue:Indo violet illustrates increased intracellular Ca
2+
 levels. (Left) Changes of extra and intracellular 
calcium in total (N=6 per treatment). (Right) Extracellular calcium was depleted by EGTA, so in the 
first phase only calcium release from intracellular sources is recorded. Restoring the extracellular 
calcium (indicated by an arrow) results in spontaneous calcium uptake (N=4 per treatment). 
Representative results are depicted.  
Although the ratio decreased over time the observed changes were very small. A real 
signalling event would result in a 10-fold change of this ratio. Furthermore, there was 
no difference between Dex- and PBS-treated cells. We also discriminated between 
Ca2+ increase form intra- and extracellular sources. Ca2+ can be released from the 
endoplasmatic reticulum (ER) as well as influx from extracellular medium. To 
distinguish between both sources, Ca2+ was removed from the medium by use of 
EGTA containing Krebs-Ringer-solution. Stimulation in this surrounding should result 
in increased intracellular Ca2+ only when it is released from the ER. Addition of Ca2+ 
to the medium afterwards (indicated by an arrow) restored extracellular Ca2+ levels 
and the impact of extracellular Ca2+ to the signal could be determined. Also in this 
set-up we did not see any difference between Dex- and PBS-treated cells (Fig. 12 
right). After addition of extracellular Ca2+ the intracellular Ca-levels spontaneously 
increased, but also irrespective of the treatment. Collectively, our findings indicate 
that the GC-induced pathway leading to the observed morphological changes of 
effector T cells does not involve Ca2+ signalling. 
 
3.1.7. Depolarization of effector T cells is sensitive to inhibition of Phospholipase C 
To further dissect the mechanism by which the GR mediates the phosphorylation of 
ERM proteins the role of Phospholipase C (PLC) was studied. It was reported 
previously, that two kinases are capable of ERM phosphorylation, namely ROCK and 
results 
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PLC (Belkina et al., 2009; Ng et al., 2001; Ren et al., 2009). The latter one was 
reported to be rapidly activated by GC treatment in thymocytes and therefore we 
considered it a promising candidate being responsible for the observed effects.  
 
 
Fig. 13 PLC inhibition impacts on GC 
induced T cell depolarization. (A) 
Effector T cells were preincubated with 
0.25 μM U73122 or vehicle (EtOH) as a 
control for 20 min followed by treatment 
with 10
-7
 M Dex for 30 min. 
Subsequently, the cells were stained 
with Phalloidin-Alexa594 and analyzed 
by confocal microscopy (size bar: 10 
μm). Representative images are 
depicted in black and white for reasons 
of improved clarity. (B) Effector T cell 
area was determined by confocal 
microscopy in combination with ImageJ 
and is individually depicted for each cell 
(µm
2
)In addition, the mean cell area for 
each condition is depicted as a 
horizontal line. Statistical analysis was 
performed by unpaired t-test (***: p < 
0.001, n.s.: not significant). Confocal 
microscopy and analysis was performed 
by Dr. Nora Müller (Müller et al., 2013). 
Consequently, we tested whether this enzyme was involved in mediating the effects 
of the GR on the cytoskeleton by use of the PLC inhibitor U73122. Confocal 
microscopy analysis revealed that pre-incubation of effector T cells with this inhibitor 
at a concentration of 0.25 µM prevented the GC induced depolarization of effector T 
cells as shown by unaltered cell area (Fig. 13). This led to the conclusion, that PLC 
activity was required for the morphological changes induced by GCs. To determine 
whether inhibition of PLC also prevented GC-induced ERM phosphorylation, western 
blot analysis of effector T cells was performed (Fig. 14A). As expected, P-ERM levels 
results 
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increased after 30 min Dex-treatment, whereas this was not the case when the cells 


















To obtain a quantitative picture of the observed effects, the experiment was repeated 
7 times and quantified via densitometry analysis of the bands and normalization to 
the vehicle treated control (Fig. 14B). We observed a slightly increased 
phosphorylation of ERM proteins after incubation with the inhibitor alone at both 
tested concentrations (Fig. 14B), but the treatment with U73122 largely prevented the 
phosphorylation of ERM proteins after Dex incubation. Dex increased P-ERM levels 
about threefold, while after pre-treatment of the cells with U73122 P-ERM levels did 
Fig. 14 GC induced P-ERM phosphorylation is sensitive to PLC inhibitor U73122. (A) After 
pretreatment with 0.25 μM U73122 or 1.0 μM PLC inhibitor U73122 or vehicle (EtOH) for 20 min, 
effector T cells were were incubated for 30 min with 10
-7
 M Dex or PBS as a control and analyzed 
for ERM phosphorylation by western blot. In each lane equal numbers of cells were loaded; ERK 
expression served as loading control. One representative analysis is depicted. N=7 (B) 
Quantification of ERM-phosphorylation by densitometric analysis of 7 experiments. The totalled 
intensity of both ERM bands relative to ist bands in untreated control cells is depicted. (C) As 
U73122 leads to a slight phsphorylation of ERM by itself, the ratio of P-ERM in Dex-treated versus 
PBS-treated cells was calculated for effector T cells preincubated either with vehicle (EtOH) or 
0.25 μM U73122. All data are depicted as the mean ± SEM; statistical analysis was performed by 
unpaired t-test (*: p < 0.05, **: p < 0.01) (Müller et al., 2013). 
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not significantly change compared to PBS treated controls. Because treatment with 
U73122 by itself slightly induced ERM phosphorylation, a ratio between Dex- and 
PBS-treated control cells was calculated for vehicle (EtOH) and U73122 (0.25 µM) 
treated cells (Fig. 14C). The relative P-ERM levels were significantly reduced after 
pre-incubation with PLC-inhibitor. Collectively, our data suggest that the GC-induced 
T cell polarization is presumably mediated by PLC-dependent ERM phosphorylation. 
3.1.8. Repression of transmigration and APC conjugation by GCs depends on PLC 
activity 
Since PLC inhibition interfered with morphological alterations and ERM activation, we 
tested whether PLC was also required for GC-induced inhibition of transmigration 
and T cell:APC conjugate formation. As described earlier, treatment of effector T 
cells with GCs led to an impaired transmigratory behaviour in a transwell system. 
After Dex treatment, the number of T cells that had migrated into the lower chamber 
were significantly reduced. When PLC inhibitor was added to the effector T cells 20 
min prior to Dex treatment at a concentration of 0.25 µM the GC-induced reduction of 
transmigration was prevented (Fig. 15A).  
In agreement with our earlier findings conjugate formation as assessed by FACS 
analysis of eGFP expressing effector T cells with labelled APCs was reduced by 
pretreatment of the effector T cells with Dex. Importantly, this feature of GCs was 
prevented by preincubation with 0.25 µM U73122 as well (Fig. 15B). The inhibitory 
effect of Dex on conjugate formation after 30 and 60 minutes was abolished at both 
time points after blocking PLC although statistical significance was not reached at the 
30 min timepoint (Fig. 15A,B). We conclude that the inability of Dex to induce effector 
T cell depolarization in the absence of PLC activity also prevented the effects of Dex 






3.1.9. GCs induce effector T cell depolarization in vivo which correlates with their 
disappearance from peripheral blood 
To test whether the observed morphological and behavioural changes might also be 
of relevance in vivo, effector T cells isolated from eGFP expressing UGC Lewis rats 
were generated and transferred intravenously in naïve syngeneic eGFP negative 
recipients and allowed to equilibrate for 48 h. Thereafter the rats were injected i.v. 
with Dex at a dose of 20 mg/kg. Afterwards, lymph node cells were isolated 0, 4 and 
24 h after Dex administration. Based on eGFP expression the transferred effector 
T cells could be discriminated from naïve recipient T cells. The re-isolated effector 
T cells were analysed by confocal microscopy (experiment performed by Nora Müller, 
University of Würzburg). Interestingly, the re-isolated effector T cells had adopted a 
round shape phenotype as seen before in vitro (Fig. 16A). 
Fig. 15 The inhibitory effects of Dex on transmigration and APC conjugation are abolished by 
inhibition of PLC (A) Preincubation of effector T cells with 0.25 μM U73122 or vehicle (EtOH) for 
20 min before the treatment with 10
-7
 M Dex for 0, 30 or 60 min reduced the inhibitory action of Dex in a 
transmigration assay. Effector T cells were allowed to migrate for 3 h without further treatment. The 
number transmigrated cells after treatment with the vehicle control (EtOH) was set to 100%. N = 4 (one 
out of four independent experiments is depicted). (B) eGFP expressing effector T cells were treated with 
10
-7
M Dex for 0, 30 or 60 min after 20 min incubation with U73122 or the vehicle control (EtOH). 
Thereafter the cells were allowed to form conjugates with MBP-pulsed APCs without further treatment. 
Staining of the APCs with anti-Thy1-PerCp and FACS analysis allowed to identify conjugates as 






Already 4 h after treatment, the transferred effector T cells had become smaller. After 
24 h this effect was even more pronounced as almost all re-isolated effector T cells 
had retracted their lamellipodiae and adopted a similar shape as naïve T cells, 
indicating that the observed morphological changes as the rearrangement of the 
cytoskeleton that we had observed in vitro also take place in vivo (Fig. 16A). As we 
had found also profound changes in effector T cell behaviour as transmigration, we 
wanted to determine the influence of GC treatment on the number of circulating 
effector T cells. To this end, eGFP expressing effector T cells were transferred 
intravenously into naïve wt rats and allowed to equilibrate for 48 h. Afterwards, the 
recipient rats were treated with 20 mg/kg Dex and peripheral blood was drawn after 
1, 3, 6 and 12 h. The number of effector T cells per blood volume prior to Dex 
treatment was set to 100% in each case and the relative number of eGFP expressing 
effector T cells was calculated for each time point (Fig. 16B). Interestingly, after 3 h 
of treatment the number of circulating effector T cells was reduced by approximately 
half and declined even further after 6 and 12 h of treatment. As the disappearance of 
Fig. 16 GCs induce depolarization of effector T cells in vivo and lead to their disappearance 
from the peripheral blood. (A) eGFP-transgenic effector T cells were injected into rats followed by 
administration of 20 mg/kg Dex 48 h later. Subsequently, lymph node T cells were isolated at the 
indicated time points by magnetic cell sorting, stained with Phalloidin-Alexa595 and analyzed by 
confocal microscopy. The diameter of the effector T cells was analyzed. This experiment was 
performed by Nora Müller (University of Würzburg) using our effector T cells. (B) 1  10
7
 eGFP-
transgenic effector T cells were adoptively transferred into rats and Dex was injected intravenously at 
a dose of 20 mg/kg 48 h later. The number of eGFP+ effector T cells in the blood was determined by 
FACS analysis of peripheral blood samples from the tail vein obtained at the indicated time points 
after Dex treatment. The average number of eGFP+ effector T cells per volume of blood at the time 
point of Dex injection was set as 100%. N = 5, pool of two independent experiments. All values are 
depicted as the mean ± SEM; statistical analysis was performed by unpaired t- test (***: p < 0.001, 
n.s.: not significant (Müller et al., 2013). 
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the effector T cells follows the same dynamics as the cytoskeleton rearrangements in 
vivo, we conclude that both mechanisms happen back to back.  
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3.2. Role of the Insulin Receptor for the modulation of T cell function in 
vitro and in vivo 
The immune system as well as several other body functions is regulated by 
hormones. Besides steroid hormones it has also been known for many years that 
dysregulation of insulin responsiveness leads to an increased risk of infections 
(Calvet and Yoshikawa, 2001; Joshi et al., 1999; Shah and Hux, 2003). As 
lymphocytes undergo profound morphological changes upon activation that are 
energy consuming, it is likely that disturbed metabolism impacts on lymphocyte 
function. 
To investigate regulation of immune responses by insulin, a rat model with inducible 
and reversible insulin receptor knockdown (InsR kd) was used (Herold et al., 2008). 
In all cases eGFP transgenic rats served as wildtype (wt) controls. The knockdown 
was always induced in vivo by providing Doxycycline containing food pellets for 5 
days prior to T cell isolation. In 
addition, Dox was added at a 
concentration of 2 µg/mL to the 
cell culture medium. To test that 
the knockdown of the insulin 
receptor (InsR) was successful, 
blood glucose levels were 
determined before T cell isolation. 
Usually 4-5 days after the 
induction of the InsR knockdown 
blood glucose levels were 
strongly elevated and the rats 
started to become diabetic (Fig 
17). 
 
3.2.1. Early activation of CD4+ T cells is impaired in the absence of InsR 
To elucidate the role of the InsR for the modulation of immune responses and T cell 
function the expression of the InsR in T cells was characterized. To this end, CD4+ T 
cells were isolated from naïve eGFP expressing UGC-Lewis (wt) or InsR kd rats and 
stimulated in vitro by use of an anti-TCR antibody (R73) in combination with an anti-
Fig. 17 Blood glucose levels after Doxycyline 
treatment. InsR knockdown (InsR) and eGFP transgenic 
UGC (wt) rats were fed with Dox containing diet ad 
libitum. The InsR kd rats showed elevated blood glucose 
levels from day three of treatment on and started to 
become diabetic at day 4. N=4 (InsR) and 2 (wt).  
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CD28 (JJ316) antibody. By western blot analysis we could show that this 
costimulation induced InsR expression in naïve T cells in vitro, which was prevented 
after inactivation of the InsR (Fig. 18). Equal numbers of CD4+ T cells were loaded in 
each lane and β-tubulin expression served as a loading control.  
Because Akt is a central player in InsR signalling, we also analysed the P-Akt levels 
(data not shown). As we were not able to detect differences in the Akt 
phosphorylation, we decided to keep the cells under serum starved conditions for 1, 
2 and 3 h to lower the basal levels of Akt phosphorylation and to unmask differences 
between wt and InsR deficient T cells. Also with this approach we were unable to 
demonstrate any differences on the P-Akt level between wt and InsR kd T cells, 
indicating that InsR deficiency has no profound impact on this signalling molecule, at 
least under the employed strong stimulating conditions (Fig. 18). 
 
 
Next we analysed the activation of co-stimulated CD4+ T cells by FACS making use 
of the activation markers CD25 and CD134. The first one is the IL-2 receptor α-chain 
and up-regulated upon T cell stimulation. CD134, also known as Ox-40, is a T cell 
specific activation marker. FACS analysis of co-stimulated wt and InsR kd CD4+ T 
cells revealed that lack of InsR led to a reduced number of CD25 single positive cells, 
which indicates that the first phase of T cell activation was impaired (Fig. 19A). 
Fig. 18 Western blot analysis of anti-TCR/-CD28 costimulated CD4+ T cells. On day 3 of 
stimulation the cells were harvested and kept under serum starved conditions for the indicated 
periods of time. Subsequently, the cells were lysed and western blot analysis was performed. Equal 
numbers of cells were loaded in each lane, β-tubulin expression served as loading control. 
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Interestingly, at later states of T cell activation as indicated by co-expression of both 
CD25 and CD134 lack of the InsR had no influence (Fig. 19B). 
 
 
Stimulated T cells undergo dramatic cytoskeleton changes that are essential for their 
function (Billadeau et al., 2007) but energy consuming. Also the stimulation of naïve 
T cells in vitro leads to morphological alterations. To visualize these changes, 
confocal microscopy of naïve and stimulated eGFP expressing CD4+ T cells was 
performed. The freshly isolated CD4+ T cells are small and round-shapes, whereas 
as early as 2 day after co-stimulation the T cells started to expand and increased in 
size (Fig. 20). As this co-stimulation via TCR/CD28 is antigen-independent and 
happens without the help of APCs, the CD4+ T cells did not adopt a polarized 
structure with lamellipodiae and uropod, but rather became T cell blasts. The cell size 
increase is in line with the up-regulation of the InsR protein, which was usually 
observed from day one of co-stimulation on. Analysis of T cell size by FACS did not 
reveal differences between wt and InsR kd cells, pointing towards a minor role of the 
InsR in the size increase, at least under the employed stimulating conditions. Of note, 
detection of the InsR by FACS using insulin labelled with a fluorescent dye failed, so 
up to now it is not possible to determine at which activation state T cells express the 
InsR. 
Fig. 19 InsR knockdown impedes early activation of T cells, whereas later activation steps are 
unaffected. Naïve CD4
+
 T cells were isolated from lymph nodes of either InsR knockdown (InsR) or 
eGFP transgenic (wt) rats and activated via TCR/CD28 co-stimulation for the indicated time periods. 
(A) The number of CD25 single positive T cells was significantly reduced at all time points. (B) The 
number of T cells expressing both CD25 and CD134 was not affected by the InsR knockdown 
compared to wt. N=12 per genotype. All data are depicted as mean ±SEM; statistical analysis was 
performed by unpaired t-test (**:p<0.05, ***:p<0.01, n.s.= not significant). 
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Collectively, the InsR is up-regulated during T cell activation and its absence delays 
the generation of CD25+ T cells. However, CD25+/CD134+ double positive cells are 
generated equally efficient. 
 
 
Fig. 20 Co-stimulated CD4
+
 T cells undergo morphological changes. Confocal microscopy of 
eGFP expressing CD4
+
 T cells before (day 0) and after co-stimulation (day 1-3) with anti-TCR/CD28 




3.2.2. InsR deficiency has no impact on T cell survival 
Besides activation also survival might be affected by InsR deficiency. Therefore 
apoptosis of naïve peripheral T cells was assessed under different culture conditions. 
To determine the spontaneous apoptosis rate of the T cells in culture, they were 
cultured under normal medium conditions using RPMI++ (supplemented with 10% 
FCS, Fig. 21A), stained with the apoptosis markers AnnexinV and 7-AAD and 
analysed by FACS. The percentage of live T cells decreased slightly during the five 
day period of cultivation. However, no difference was seen between wt and InsR kd 
cells. To analyse stress induced apoptosis in vitro the T cells were cultured under 
serum starved (1% FCS) or serum-free conditions. Serum deprivation led to 
apoptosis of T cells of either genotype. 1% FCS only slightly induced apoptosis 
whereas complete lack of serum led to cell death within the first two days of culture, 








Fig. 21 InsR knockdown has no impact on T cell survival in vitro. Primary T cells were isolated 
from eGFP transgenic UGC (wt) or InsR knockdown (InsR) rats. Apoptosis was assessed by staining 
of the T cells with Annexin V (AxV) and 7-AAD following FACS analysis. The number of late apoptotic 
cells (double positive) is depicted. (A) Spontaneous apoptosis in normal RPMI++ medium (10% FCS). 
(B) Rate of apoptotic cells after incubation under serum starved conditions (1% FCS). (C) Percentage 
of apoptotic T cells after cultivation under serum-free conditions. 
 
Furthermore, apoptosis was induced using irradiation. To this end, isolated wt or 
InsR kd CD4+ T cells were irradiated at different doses and cultured in standard 
RPMI++ medium for five days. 
The T cells underwent apoptosis in a dose dependent manner. Interestingly, also 
with this apoptosis stimulus no genotypic differences were observed (Fig. 22A). This 
held also true for GC induced apoptosis. The T cells were cultured with increasing 
doses of Dex and apoptosis was assessed on three consecutive days. At all time 
points, no difference between wt and InsR kd T cells was observed, day two is 
depicted as a representative example (Fig. 22B). This indicates that the InsR seems 













Fig. 22 Survival of T cells 2 days after apoptosis induction by irradiation and GCs. (A) CD4
+
 
T cells were exposed to different doses of irradiation. The percentage of AxV and 7-AAD negative 
T cells is depicted. (B) CD4
+





3.2.3. The InsR is no longer expressed during long term activation 
The hitherto obtained results suggested that the InsR was required during early T cell 
activation but not for their survival. As the energy demand increases during activation 
and also during ongoing immune responses, it is likely that the InsR impacts on T cell 
function. To determine the involvement of the InsR in these processes, ongoing 
inflammatory responses should be analysed. In vivo models are challenging, 
because a complete knockdown in all tissues as it is present in our model leads to 
the manifestation of a type 2 diabetes like phenotype, as all tissues are not longer 
sensitive to insulin. Therefore we decided to initially focus on InsR deficient effector T 
cells by generating encephalitogenic T cells.  
To this end, transgenic InsR kd rats were immunized with gpMBP emulsified in CFA 
to trigger an antigen-specific immune response. 10 days later the activated CD4+ 
T cells were isolated from the draining lymph nodes and propagated in culture. To 
ensure their antigen-specificity, they were re-stimulated twice with gpMPB (Fig. 23). 
These cells were tested for their functional competence by inducing AT-EAE and 
were found to be as effective as wt effector T cells. The severity of the induced 
disease correlated with the number of injected effector T cells (Fig. 24A). FACS 
analysis of the encephalitogenic T cells after the second re-stimulation confirmed that 
the newly generated cells were T cells that all expressed the activation marker CD25, 
and more than 70% of the cells were also positive for CD134. Furthermore, nearly all 
cells lost expression of the adhesion molecule CD62L, which is expressed on resting 
cells (Fig. 24B). 
 
 
Fig. 23 Scheme for InsR kd effector T cell generation. InsR kd rats were immunized with gpMBP 
emulsified in CFA. 10 days later, before the first EAE symptoms occur, the activated gpMBP-specific T 
cells were isolated from the draining lymph nodes and re-stimulated with APCs pulsed with gpMBP. 3 
days later the encephalitogenic T cells were purified via a cold gradient and expanded for another 3 
days. After a second re-stimulation phase and purification, the encephalitogenic T cells were used for 






Prior to the kockdown induction by addition of Dox, the generated InsR kd T cells 
were of similar to wt cells. To analyse the impact of InsR kd during EAE, the gene 
inactivation had to be induced prior to AT-EAE in the cells and also had to be 
maintained in the host’s system during the EAE (Fig. 25). For the first in vivo 
experiments, we decided to use a medium number of transferred effector T cells to 
induce a moderate AT-EAE (3  106 T cells). Thereby it would be possible to observe 
effects of the knockdown in both directions. The knockdown was induced by in vitro 
treatment of the cells with 2 µg/mL Dox in the medium during the re-stimulation of the 
cells (Fig. 25). 
 
Fig. 25 Scheme of InsR knockdown induction in effector T cells and AT-EAE. After purification of 
the encephalitogenic T cells they were expanded in TCGF medium containing 2 µg/mL Dox for three 
days. Afterwards, the encephalitogenic T cells were re-stimulated for three days with gpMBP-pulsed 
APCs also in the presence of 2 µg/mL Dox and again purified with a cold gradient. The freshly re-
stimulated cells were used for AT-EAE induction by i.v. injection into wt rats receiving Dox containing 
diet ad libitum throughout the experiment. 
Fig. 24 Analysis of the newly generated InsR kd effector T cells. (A) Adoptive transfer EAE to test 
the newly generated InsR kd effector T cells. Newly generated InsR kd effector T cells were transferred 
intravenously to naïve Lewis rats at different amounts and the disease symptoms were assessed using 
a 10 grade scoring scale. (B) FACS analysis of the newly generated effector T cells after the second re-
stimulation confirming the expression of classical surface markers of activated T cells (CD25, CD134). 
The adhesion molecule CD62L is down-regulated upon stimulation and also not expressed on the 
tested effector T cells. 
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After purification of the encephalitogenic T cells they were injected intravenously into 
wt recipient rats receiving Dox containing food pellets to maintain the knockdown 
throughout the AT-EAE (Fig. 25). Non-Dox treated InsR kd effector T cells served as 
a control. Both groups did not differ in severity or duration of the EAE symptoms. Of 
note, treatment of AT-EAE induced with wt cells with Dox had no influence on the 
disease, indicating that Dox alone does not impact on EAE i.e. via modulation of 
bystander cells (data not shown).  
 
 
Unexpectedly, Dox treatment did not affect the disease severity in AT-EAE (Fig. 
26A). Between both groups also no differences were observed in the body weight 
changes (Fig. 26B).  
Since the InsR had been found to be up-regulated during T cell stimulation we 
expected that the InsR would also be expressed in repeatedly activated effector 
T cells and that this would impact on their pathogenicity. To verify InsR expression in 
those cells, we lysed eGFP transgenic wt effector T cells either directly after 
restimulation (d3) or expansion (d6, see Fig. 23) and analysed InsR protein levels by 
western blot. Liver cell lysate and co-stimulated CD4+ T cells served as positive 
controls. Intriguingly, in none of the tested wt effector T cell lines we were able to 
detect any InsR protein (Fig. 27A). Also additional stimulation of these long-term 
activated T cells with anti-CD28/anti-TCR co-stimulation as described above for 
naïve CD4+ T cells was unable to induce InsR expression. We also tried to other 
ways to stimulate the encephalitogenic T cells in order to induce InsR expression, but 
Fig. 26 Adoptive transfer EAE with InsR kd effector T cells. 3  10
6 
newly generated effector T cells 
were injected i.v. into wt recipient rats to induce a moderate AT-EAE. The encephalitogenic T cells were 
either pre-treated with Dox and injected into wt rats receiving Dox-containing diet or left untreated. The 




also after activation with the mitogen ConA or with the superagonistic CD28-antibody 
JJ316 (Lin and Hünig, 2003), reagents known to stimulate T cells antigen-
independently, we were not able to detect any InsR protein (Fig. 27B). Of note, 
stimulation with ConA or JJ316 also failed to induce InsR expression in naïve CD4+ 
T cells. To further investigate this unexpected finding, the expression of InsR mRNA 
was assessed by qrtPCR. RNA of naïve and co-stimulated CD4+ T cells of both 
genotypes as well as wt effector T cells was analysed for the relative abundance of 
InsR mRNA. The amount of InsR transcripts was calculated relative to β-actin 
transcripts serving as a housekeeping gene. Interestingly, in naïve CD4+ T cells from 
both wildtype and Dox treated InsR kd rats, the InsR mRNA was constitutively 
expressed, although the InsR protein levels in the latter ones were dramatically 
reduced after knockdown induction (Fig. 27C). Co-stimulation of these cells did not 
lead to an mRNA up-regulation but rather a down-regulation, all together suggesting 
a translational rather than transcriptional regulation of InsR protein expression. 
 
 
Fig. 27 Effector T cells lack InsR 
expression on both protein and 
mRNA level. (A) Naïve CD4
+
 T cell 
lysates and effector T cells lysed 
after restimulation (d3a,b) or 
following proliferation (d6a,b) were 




cells and liver cells served as 
positive controls. This experiment 
was performed twice. (B) Western 
blot analysis of naïve and effector T 
cells after 3 days of different 
stimulation. one representative blot 
out of two independent experiments 
is depicted. (C) RNA was isolated 
form naïve or co-stimulated T cells 
of both, wildtype and InsR kd rats, 
as well as from effector T cells at 
three different stages (freshly 
isolated, after the first and the fifth 
restimulation) and InsR expression 
was assessed by qrtPCR. Data is 
depicted as mean ±SEM; statistical 
analysis was performed by unpaired 





Furthermore, mRNA expression in freshly isolated effector T cells (10 days after 
immunization) was reduced by half (“fresh”, Fig. 27C) and further decreased during 
the subsequent re-stimulation cycles (1 and 5 re-stimulated).  
Taken together, the InsR protein expression seems to be regulated on the 
translational level. During long term activation or maintenance of the activated status 
of effector T cells the InsR seems to be dispensable, as its transcription is stopped. 
 
3.2.4. Treg cell function in InsR kd animals is unaltered 
Metabolism integrated with T cell function (Gerriets and Rathmell, 2012). This could 
lead to an impaired function of Treg cells, which prevent autoimmune reaction under 
normal conditions. To test if the Treg cells lacking the InsR are less efficient than their 
wt counterparts, a 3H-thymidine suppression assay was performed. In this assay 
target cells are activated in an antigen-independent manner using ConA and mixed 
with different amounts of Treg cells that suppress the proliferation of the target cells. 
As only about 5% of all T cells are Treg cells we decided to expand them in vivo to 
obtain sufficient cell numbers. To this end we took advantage of the superagonistic 
anti-CD28 antibody JJ316. When applied 3 days prior to T cell isolation JJ316 is 
known to strongly expand Treg cells (Lin and Hünig, 2003). These cells were purified 
by MACS technology and used in the in vitro suppression assay. CD4+ T cells were 
mixed with irradiated APCs and ConA to induce proliferation and served as target 
cells. Treg cells were added at different effector to target ratios and allowed to 
suppress the proliferation for 48 h. 
 
 
Afterwards the cells were pulsed with 3H-thymidine containing medium that was 
incorporated into the DNA during proliferation. Since the APCs had been irradiated 
Fig. 28 InsR kd Treg cells are as 
suppressive as their wt counterparts. 
A 
3
H-thymidine suppression assay was 
performed. Treg cells were mixed with 
activated target cells at different ratios. 
After 2 days, the cells were pulsed with 
3
H-thymidine containing medium and 
harvested and analysed 16 h later. 
Proliferation is indicated by 
3
H-thymidine 




the only proliferating population are the CD4+ target T cells. The Treg cells derived 
from both genotypes were equally effective in the suppression of ConA-stimulated 
target CD4+ T cell proliferation (Fig. 28). This led to the conclusion, that InsR 
deficiency does not cause a reduced regulatory activity of Treg cells.  
 
3.2.5. CTL function is impaired in InsR kd rats 
Besides CD4+ T cells it is also conceivable that CD8+ T cells require the InsR for 
proper function. Cytotoxic T cells (CTLs) are needed for the defence against virus-
infected cells. They fulfil their function by releasing cytotoxic molecules, a potentially 
energy-demanding process. To test whether CTLs are more sensitive to InsR 
deficiency than CD4+ T cells, a 51Cr release assay was performed. To this end, wt 
and InsR kd rats were immunized with allogenic splenocytes. This led to the 
activation of CD8+ T cells and their proliferation in the draining lymph nodes, from 
which they were isolated 10 days later. Subsequently they were exposed to 51Cr 
pulsed allogenic blasts serving as target cells. The latter ones were produced by 
stimulation of splenocytes from rats of the same genetic background that had been 
used for immunization. The stimulation causes a higher uptake of 51Cr during the 
labelling process. After mixing them, the CTLs were allowed to lyse the target cells 
for 4 h. Afterwards the supernatant was analysed in the beta counter. CTL killing 
efficiency correlated with the release of radioactivity to the supernatant. To exclude 
imprecision due to different amounts of target cells per well, the cell pellets were 
lysed and the radioactivity determined to calculate the total radioactivity per well. The 
percent release of total radioactivity was calculated and is depicted (Fig. 29). 
Interestingly, InsR deficient CTLs were less effective in the killing of target cells than 
wt cells (Fig. 29). Whereas the wt cells were able to lyse about 40% of the target 
cells at a 100:1 ratio, InsR deficient cells released less then 30% of the total 
radioactivity. Also at all other tested ratios the InsR deficient CTLs were less effective 
as their wt counterparts (p<0.01), suggesting an important function of the InsR in 








3.2.6. In vivo approach: generation of bone marrow chimeric rats 
Because all experiments conducted so far were only performed in vitro we switched 
to in vivo approaches. Effects that might not be evident under artificial culture 
conditions could come into play in immune reactions involving the interaction of 
different cellular compartments and have implications during disease progression. 
Because a complete knockdown of the InsR leads to insulin resistance in all tissues, 
a diabetes type 2 like phenotype develops in the rats. This is lethal within 6-7 days 
and therefore not suitable for in vivo approaches as most immune reactions take 
longer then this. To overcome this problem bone marrow chimeric rats were 
generated. With this method it is possible to limit the InsR kd exclusively to cells of 
the hematopoietic system and to overcome the problem of general insulin resistance. 
To this end, bone marrow was isolated from eGFP transgenic UGC (wt) or InsR kd 
rats and injected i.v. into sublethally irradiated eGFP negative recipients of the same 
genetic background. The recipient’s hematopoietic system is destroyed by the 
irradiation and so the niches in the bone marrow are free to be repopulated by donor 
cells. Reconstitution was tested by FACS analysis 4 weeks after bone marrow 
transfer. We found high reconstitution rates in all recipients. Nearly all (>95%) 
granulocytes and B cells were eGFP positive donor cells (Fig. 30). However, in the T 
cell compartment we observed about 30% eGFP negative recipient T cells. This is a 
normal abundance in bone marrow chimeric mice and rats, so we decided to use the 
Fig. 29 InsR deficient CTLs 
show reduced lytic capacity 
as compared to wt cells. A 
51
Cr release assay was 
performed using CTLs derived 
form either InsR kd or wt rats 
and exposed to 
51
Cr pulsed 
allogenic blasts at different 
effector:target ratios. The 
specific lysis as a mean of 
three independent 




chimeric rats for in vivo analyses. The rats were analysed every 4 weeks with 
comparable results at each time point.  
 
 
3.2.7. Induction of EAE in InsR kd bone marrow chimeric rats 
After successful generation of bone marrow chimeric rats first EAE experiments were 
conducted. As we had seen that the InsR seemed to be important during stimulation, 
especially in the early phase of activation, but not during long-term activation, it is 
likely that the InsR kd cells would have an impairment in the priming phase of an 
immune response rather than during the effector phase. To challenge this hypothesis 
we decided to use the model of active EAE. The effector T cells have to be primed to 
get polarized to Th1 or Th17 cells and to migrate to the target organ, the CNS. 
The hematopoietic system-specific InsR knockdown was induced in the bone marrow 
chimeric rats by Dox containing diet one week prior to immunization with gpMBP. 
During EAE the animals were weighed and scored daily. After 11 days the first EAE 
symptoms occurred. Chimeric rats reconstituted with wildtype or InsR deficient bone 
marrow both followed a monophasic disease course (Fig. 31A). The severity of 
symptoms as well as the duration of the disease did not differ between the donor 
genotypes.  
 
Fig. 30 Analysis of reconstitution after bone marrow transfer. 4 weeks after bone marrow transfer 
blood drained from the tail vein of bone marrow chimeric rats was analysed and stained for B cells 
(anti-CD45RA) and T cells (anti-TCR). Granulocytes were gated for granularity (SSC) and size (FSC). 
Subsequently, the cells were analysed for eGFP expression. Data from one representative rat out of 




During the recovery phase, a slightly higher bodyweight was observed in InsR kd 
chimeric rats, pointing towards a slightly milder disease severity in those animals 
(Fig. 31B). Nonetheless, the mean score did not differ at all between both groups. 
We conclude that InsR knockdown in hematopoietic cells, at least at the degree of 
reconstitution achieved in this experiment, had no influence on disease severity or 
duration. This suggests that the InsR is dispensable during an inflammatory response 
in this model and that increase of glucose uptake and glycolysis in effector T cells 






Fig. 31 The disease course of EAE in wt and InsR BM chimeric rats is similar. Active EAE was 
induced in BM chimeric rats reconstituted with either wt or InsR kd BM by immunization with 
gpMBP in CFA. (A) Both groups followed the same dynamics regarding the disease severity as 
assessed by a 10 grade scoring scale. (B) Relative bodyweight of the rats during EAE is depicted. 
The rats reconstituted with InsR BM showed a slightly higher weight gain during recovery N=12 per 




4.1. Endocrine control of T cell function and polarization 
Mammalian organisms are complex. Different organs fulfil different tasks for the 
benefit of the whole body. Protection against pathogens like bacteria, fungi and 
viruses as well as against tumours is conveyed by the immune system consisting of 
various cell types. Herein T cells are central players. To distribute information soluble 
messengers are necessary with hormones being one prominent example. They 
orchestrate numerous functions in the body and also impact on immune cells. This 
endocrine regulation is crucial for the whole organism, as it mediates activity as well 
as stress-responses and metabolism. T cell function and plasticity are two examples 
of hormonal key regulation as well. For example, the influence of the endocrine day-
night-cycle on lymphocyte migration and motility has been reported (Kirsch et al., 
2012).  
In this project we aimed to analyse the regulation of T cell function by endogenous 
insulin signalling as well as in response to exogenous treatment with GCs. 
4.2. Glucocorticoids interfere with effector T cell pathogenicity by 
modulation of the cytoskeleton 
GCs are steroid hormones with anti-inflammatory action and immunosuppressive 
properties. Endogenous GCs have numerous mechanisms to regulate physiological 
functions, including circadian changes of GC levels. Treatment with GCs is more 
efficient when it is conducted during the night. For instance downregulation of MMP9 
is more pronounced if GCs are applied at night-time (Glass-Marmor et al., 2009; 
Mirowska et al., 2004). Interestingly, Leukocyte trafficking is also influenced by 
circadian changes (Dimitrov et al., 2009; Kirsch et al., 2012), providing a first hint of 
migratory modulation by GCs. 
Synthetic GCs have been in use for more than 60 years for the treatment of diseases 
like asthma or MS. As broad as this range of application is the range of side-effects. 
Treatment with GCs can disturb glucose metabolism (Pidala et al., 2011), a fact that 
might impact on the whole organisms as well as on immune cells. Furthermore GCs 
can cause osteoporosis (Canalis et al., 2007) or generally an increased infection-risk 
due to the immune suppression. 
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In view of these complications it is desirable to further dissect the mechanisms of 
GCs. It has been believed for decades that apoptosis is a central mechanism, but 
recently increasing evidence arose that this might not be the case (reviewed in 
(Reichardt and Lühder, 2012). 
Besides the genomic effects of the GR, namely transrepression and transactivation 
of target genes, also non-genomic effects of the GR came into focus. These effects 
are independent of transcriptional modulations and could therefore potentially be very 
rapid and immediate. Understanding these effects and classifying their importance 
for treatment will help to refine GC treatment, to modify drugs and to reduce side-
effects. 
 
4.2.1. Impact on T cell morphology and behaviour in the context of 
neuroinflammation 
To study the GC-induced changes in cells that are essential for the pathogenesis of 
EAE and presumably MS we have analysed effector T cells in vitro. We have shown 
profound and early changes in T cell morphology and behaviour, impacting on central 
steps in T cell responses that are also important for T cell mediated autoimmunity. 
In a first set of experiments we could show rapid morphological rearrangements of 
polarized effector T cells after high-dose GC treatment. These cytoskeletal 
modulations were detectable as early as 20 min after treatment and lasted for more 
than 3 hours. These morphological changes were also accompanied by increased 
cell rigidity (Müller et al., 2013). It is reasonable that this profoundly interferes with T 
cell function. It has been published, that T cells need a specific polarized structure in 
order to be functional (Billadeau et al., 2007; Krummel et al., 2000; Krummel and 
Macara, 2006). T cells have to be highly motile and lamellipodiae at the leading edge 
scan the surrounding. Targeted expression of chemokine receptors, integrins or 
stimulatory molecules allows directed migration. If this structure is lost and the cell 
additionally retracts and adopts the shape of a naïve cell it is obvious that this 
impacts on cellular functions. To dissect in which way the cell is influenced by GCs 
and impaired by the rearranged cytoskeleton we tested the capability of cells after 
GC treatment to conduct the central steps of autoimmune responses.  
First, we had a closer look on the transmigratory behaviour of effector T cells before 
and after treatment. As expected, GC-treated effector T cells exhibited a strongly 
reduced migratory capacity. After 20 min of treatment migration was already 
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significantly reduced and after 3 hours even diminished by half. Transmigration out of 
the blood vessel into the Virchow space and subsequently into the CNS is important 
in MS and EAE development (Engelhardt, 2008). Interfering at this early stage, even 
before the T cells are reactivated in the CNS by their cognate antigen is one possible 
mode of action of GCs. A second effect of altered T cell migration might be re-
direction. Adequate chemotaxis to the site of inflammation is an integral part of T cell 
responses. GCs impact on cytokine receptor expression and thereby might increase 
or decrease the response to certain cytokines (Schweingruber et al., submitted). 
Another step in T cell activation is the interaction with APCs. These cells present 
antigen and provide the indispensable second signal for T cell activation. If T cells fail 
to receive this signal they are not sufficiently stimulated and become anergic. In order 
to interact with APCs, T cells have to rearrange surface molecules and to direct TCR, 
co-receptors, co-stimulatory molecules and chemokine receptors towards the partner 
cell. For all these processes T cell polarization is a prerequisite (Billadeau et al., 
2007). A more rigid, less flexible cytoskeleton with a tightly linked F-actin filament 
might interfere with the proper assembly of APC-T cell conjugates. To test this notion 
we have established a method to quantify such conjugates using FACS technology. 
In this case the results were even more dramatic, since only 10 minutes of GC 
treatment reduced the number of conjugates by half. This effect was maintained for 
all tested time points up to 3 hours.   
To elucidate the underlying mechanisms we analysed proteins, which are potential 
targets of GCs. Proteins of the ezrin-radixin-moesin family (ERM-proteins) are 
candidate molecules (Allenspach et al., 2001; Delon et al., 2001; Roumier et al., 
2001). In T cells two members of this family, namely ezrin and moesin, are 
expressed. In resting cells, the proteins are highly phospholylated and provide 
crosslinks between F-actin-filaments and plasma membrane (Bretscher et al., 2002; 
Gautreau et al., 2002). The result is a stable morphology with optimal volume to 
surface ratio. Upon TCR engagement, the proteins are rapidly dephosphorylated, 
allowing for dynamic rearrangements of the cytoskeleton in order to adopt the typical 
morphology of effector cells (Delon et al., 2001). For T cells this is a structure with a 
leading edge expressing antigen-receptors and cytokine-receptors that enables 
directed migration. All dispensable surface molecules are collected at the opposing 
pole at the distal pole complex (DPC). Re-phosphorylation of ERM-proteins would 
reverse this modulations and therefore provide an explanation of the observed effect 
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of GCs. Western blot analysis of P-ERM revealed that effector T cells have only a 
low level of phosphorylation that is rapidly and strongly increased after GC treatment. 
As expected the effects were immediate and occurred as early as five minutes after 
treatment, further increasing within the first 30 minutes and then slightly declining. 
This mechanism is, of note, in line with the results of cell rigidity analysis (Müller et 
al., 2013) and provides an explanation for morphological alterations and for impaired 
transmigratory capacity. The proteins ezrin and moesin are essential for DPC 
formation and IL-2 production as well (Shaffer et al., 2009). In addition, TCR-induced 
de-phosphorylation of ERM-proteins supports the interaction with APCs (Faure et al., 
2004) and therefore is in line with our findings mentioned above. A second potential 
mechanism for the cytokleletal modulation induced by GCs is phosphorylation of FAK 
(Koukouritaki et al., 1999), which could also contribute to the rearrangement of the 
cytoskeleton. For mouse T cells it has been shown that FAK is indeed 
phosphorylated after GC treatment (Schweingruber et al., submitted). 
The signalling cascade that induces the morphological changes by phosphorylation 
of ERM proteins could be induced by the GR or represent an unspecific off-target 
effect of GCs. To distinguish between both possibilities we made use of siGR effector 
T cells (Tischner et al., 2009). These cells have no GR protein and could therefore 
only show unspecific effects. Intriguingly, when these siGR effector T cells were 
treated with GCs we did not observe any changes in P-ERM-levels. This suggests, 
that the observed effects are indeed mediated by the GR. Furthermore, those cells 
also failed to show morphological alterations. After GC treatment they maintained 
their polarized structure, leading to the conclusion that the GR is essential for GC 
mediated depolarization (Müller et al., 2013). 
But how does the GR induce the morphological changes? Intracellular signalling is 
very complex. Key molecules can take part in more than one pathway and second 
messengers are a common feature to rapidly transmit information within the cell and 
to amplify signals. One important second messenger in lymphocytes as well as all 
other cells are Ca2+-ions. They can be released from intracellular sources or influx 
from the extracellular space through Ca2+-channels. We analysed whether the GC-
induced signalling cascade leading to ERM-phosphorylation was accompanied by 
Ca2+-signalling. Therefore we determined the level of intracellular Ca2+-ions with a 
Ca-sensitive dye and monitored the levels over time after GC treatment. In none of 
the analyses we were able to observe a significant shift in Ca2+-levels and we 
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conclude from this that the GR-mediated signalling is independent of Ca2+-ions as 
second messenger. 
The next question to be answered was which enzyme was responsible for ERM-
phosphorylation. It was reported that two kinases could potentially mediate this 
phosphorylation, namely ROCK and PLC (Belkina et al., 2009; Ng et al., 2001; Ren 
et al., 2009). It has been published that PLC was activated after GC treatment in 
thymocytes and therefore it was a promising candidate in our model (Cifone et al., 
1999). By pre-incubating effector T cells with the PLC-inhibitor we were able to 
obviate the effector T cell rearrangements. The inhibitor interfered with the GC-
induced cell size reduction as well as with depolarization. At the molecular level it 
also prevented the GC-induced ERM-phosphorylation. Furthermore, the 
transmigratory capacity as well as the ability to form APC conjugates was preserved 
if the cells were treated with the inhibitor. Collectively, the GC-mediated cytoskeletal 
rearrangements are induced by the GR activating PLC to phosphorylate ERM-
proteins. 
The GR could potentially mediate its effects either by modulation of transcription or 
by non-genomic effects. In both cases the GR is released from cytosolic heat shock 
proteins after binding of GCs (Herold et al., 2006). Transcriptional modifications can 
be divided in transactivation and transrepression. The first one is mediated by direct 
interaction of a GR-homodimer with a DNA region, the GC responsive elements 
(GRE) and acting as an activator, whereas the latter one is mediated by interaction 
with transcription factors without DNA-binding leading to suppression of transcription 
(see Fig. 3). On the other hand the GR can act in the cytosol where it mediates non-
genomic effects (Herold et al., 2006). These GR actions are only recently being 
explored (Buttgereit and Scheffold, 2002). To characterize the GR action that is 
important for the newly identified impact on the effector T cell cytoskeleton one can 
inhibit translation in order to distinguish between gene-modulating effects and those 
independent of transcription. Treatment of effector T cells with the translational 
inhibitor cycloheximide (CHX) did not affect the GC induced cytoskeletal 
modifications (Müller et al., 2013) suggesting a non-genomic action of the GR 
(Koukouritaki et al., 1999).  
To test whether this newly discovered mechanism is also of relevance in vivo, a first 
step was to analyze whether effector T cells also undergo cytoskeletal 
rearrangements if those are applied systemically. During EAE, GC treatment 
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ameliorated the symptoms, but it is difficult to follow the fate of single effector T cells 
over time. To overcome this problem we induced AT-EAE with a pure effector T cell 
population expressing eGFP to allow identification of the transferred T cells after 
treatment. Intriguingly, transferred effector T cells responded to GCs in the same 
manner that we had observed in vitro. The cell size of the re-isolated cells drastically 
decreased after treatment. This was accompanied by disappearance of the cells from 
the blood, suggesting that not only polarization, transmigration and APC-conjugation 
are affected but also circulation of the cells. The latter feature would be in line with 
the findings in mice, that redirection is a central part of the beneficial effects of GCs 
(Schweingruber et al., submitted). 
Finally, there is also initial evidence that altered migration of T cells might be of 
relevance for the treatment of human MS patients. Recently more and more the 
expression pattern of chemokine receptors came to focus in MS research (Dos 
Santos et al., 2008; Holman et al., 2011). GCs induce expression of CXCR4 and 
increase migration towards SDF-1. This would be a second line how GCs modulate 
effector T cell migration. There are also first experiments showing that also T cells 
obtained from human MS patients show the same cytokine response compared to 
mice or in vitro treated cells (Schweingruber et al., submitted). This suggests that this 
is a stable, species independent mechanism. 
 
4.2.2. Conclusion 
Our findings suggest that GCs act in a two-step manner in repressing T cell 
responses. Here we have identified a first immediate and rapid action of GCs by 
which they directly interfere with effector T cell function. Within minutes after 
treatment, the GR activates the kinase PLC in a non-genomic manner (Fig. 32). This 
pathway does not trigger Ca2+ signalling. PLC activation leads to the phosphorylation 
of ezrin and moesin (Fig. 32), an event that leads to crosslinking of the F-actin 
cytoskeleton with the plasma membrane. As a result, the characteristic polarized 
structre of effector T cells is lost. The lamellipodiae retract, thereby inhibiting targeted 
expression of surface molecules. The cells lose the flexibility and rigidity increases. 
Subsequently the transmigratory capacity as well as the interaction with APCs are 
dramatically reduced. Taken together, GCs influence T cell function and migration on 
several levels. This non-genomic effect is presumably a first wave of GC action that 




Fig. 32 GC mediated effects on effector T cells. T cell receptor (TCR) stimulation leads to the 
dephosphorylation of proteins of the ezrin-radixin-moesin (ERM) family, which results in the 
rearrangement of the cytoskeleton. Consequently, T cells adopt a polarized structure with a 
leading edge formed by lamellipodiae, an opposing pole containing the distal pole complex 
(DPC) and directed expression of surface molecules and receptors. GCs might interfere with 
these morphological alterations of T cells by increasing ERM phosphorylation leading to 
crosslinking of F actin and plasma membrane and thereby mediating the depolarization. 





4.3. Metabolic regulation of T cell function 
The overall metabolic status impacts on a variety of cell types as well as T cell 
function. As mentioned above, T cells undergo profound morphological alterations 
upon activation. The cytoskeleton is rearranged to provide the optimal structure for 
effector T cells, receptors are up-regulated and cytokines are expressed. Different 
types of T cells have different requirements, determined by the cytokine milieu and 
the education provided by the activating APC. The different T cell subsets to which 
the naïve cell can differentiate is determined by transcription factors and results in 
the expression of specific cytokines of effector molecules. All cells have in common 
that activation is energy-consuming and the cells have to meet their demand. 
To cover increased energy expenditure, the cells eventually switch their metabolic 
paradigm during activation from oxidative phosphorylation to glycolysis (Brand et al., 
1986; Wang and Green, 2012; Wang and Green, 2012). Thereby they switch from an 
oxygen-dependent to an oxygen-independent metabolism (Caldwell et al., 2001). 
This enables them to migrate and survive under hypoxic conditions as found in 
inflamed tissues. They also up-regulate the glucose transporter Glut1 and glycolytic 
enzymes (Marko et al., 2010; Vander Heiden et al., 2009). This provides a potential 
link between insulin metabolism and T cell function: InsR engangement also leads to 
up-regulation of glucose transporter (Glut4) and to increased glycolysis. Lack of 
InsR-signalling could therefore be a disadvantage in highly energy-consuming 
immune reactions. 
There is increasing evidence that there is a tight link between T cell activation and 
metabolism (Fox et al., 2005). Several recent studies focussed on the metabolic 
control of T cell migration (Mora and von Andrian, 2006; Sinclair et al., 2008), i.e. 
transgenic overexpression of the Glut1 transporter led to an augmentation of T cell 
activation (Jacobs et al., 2008). It is therefore quite likely that the energy supply 
impacts on the T cell function and fate. To address this issue, one could either 
culture T cells under different metabolic conditions and test their functionality or use 
T cells that cannot respond to certain stimuli. In our studies we made use of InsR kd 
cells, that are deficient for the InsR. We analysed different T cells subsets for their 




4.3.1. Impact of InsR signalling on Th cells 
Differentiation into Th cell subsets is at least in part determined by metabolic 
pathways of the T cell (Fox et al., 2005; Frauwirth and Thompson, 2004; Plas and 
Thompson, 2005; Wang and Green, 2012). 
If no extrinsic signals induce increased nutrient uptake the cells eventually undergo 
apoptosis (Ciofani and Zuniga-Pflucker, 2005; Rathmell et al., 2000). It has also been 
shown that the induction of glucose uptake is critical for effector T cell survival (Cham 
and Gajewski, 2005). Insufficient glucose supplement leads to defective effector T 
cell function and the induction of pro-apoptotic proteins such as Noxa and Bax (Alves 
et al., 2006; Chi et al., 2000). 
In all experiments we have consistently observed an impairment of InsR deficient 
CD4+ T cells to up-regulate the activation marker CD25. Interestingly, expression of 
the later activation marker CD134 was not affected by the lack of the InsR. Further 
analysis by western blot confirmed InsR expression in co-stimulated wt CD4+ T cells 
and its absence in the InsR kd cells. Up to now, we are not able to distinguish 
between the different phases of T cell activation using this method. So it would be 
possible that the InsR is predominantly expressed during early activation and not or 
less pronounced in the later stages of T cell activation. The in vitro stimulation is 
artificial and very strong and therefore may differ from physiological conditions in 
terms of InsR expression. In our setting the cells might initially up-regulate the InsR 
to meet their demand but are subsequently no longer dependent on its expression. It 
might also be that the high amount of IL-2 in the culture influences the cells in a way 
that insulin has no further impact on metabolism. Another explanation might be that 
the cells are constitutively stimulated via CD28 due to the presence of the anti-CD28 
antibody in our system and that InsR deficient cells can compensate for the absence 
of InsR signalling or that the overall-signalling is so strong that it conceals all effects 
of the InsR inactivation. Stimulation without CD28 engangement results in an overall 
weak activation of cells, but without showing differences caused by InsR deficiency. It 
is known, that the switch from oxidative phosphorylation to glucose matabolism is 
dependent on CD28 stimulation (Frauwirth et al., 2002; Jacobs et al., 2008), so it is 
not surprising that there is no difference observable, as cells of neither genotype 
presumably utilize glucose.  
We also failed to observe differences in the cell’s ability to increase in size after 
stimulation. Both populations, wt and InsR, nicely responded to stimulation and 
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became effector T cell blasts. This would be also in line with the finding that there is 
no profound difference in the activation status of Akt as shown by western blot 
analysis for P-Akt, pointing towards a compensatory mechanism or too strong 
stimulation leading to the maximal phosphorylation of Akt.  
We aimed to analyse expression patterns of the InsR in the different stages of T cell 
activation and Th cell subsets by FACS. Analysis with commercially available InsR 
antibodies is not possible because all of them recognize a transmembrane or juxta-
membrane part of the InsR. To overcome this problem we tried to detect the InsR by 
binding of insulin to the cells. To this end we labelled insulin with a fluorochrome 
using a microscale protein labelling kit. Unfortunately, we were not able to detect any 
specific binding of the insulin, so it remains to be determined, which T cell population 
up-regulates the InsR upon activation.  
As InsR kd CD4+ T cells showed an impairment in the activation we also wanted to 
analyse T cell survival. It is known for effector T cells, that insufficient glucose uptake 
leads to the induction of apoptosis (Alves et al., 2006; Chi et al., 2000). It might also 
be that T cells lacking the InsR are per se more prone to apoptosis. Resting cells 
express no detectable amount of InsR, but under starved conditions induction of InsR 
expression might help the T cell to overcome apoptosis. We have tested different 
conditions of serum-starvation and also the overall survival of the T cells in culture. 
Under none of the tested conditions we were able to detect differences in T cell 
survival. Challenging of the cells with GCs or irradiation did not reveal any detriment 
of InsR deficient T cells as well. 
InsR expression is induced upon activation to meet the energy demands of activated 
T cells. Effector T cells strongly proliferate and secrete cytokines. Therefore we 
wanted to analyse the impact of InsR signalling on long term activated effector T 
cells. These cells should have switched their metabolism from oxidative 
phosphorylation to glycolysis, mediated by CD28 (Jacobs et al., 2008). The InsR 
signalling leads to increased glycolysis and glucose uptake so it is likely that this 
mechanism is synergistic with the CD28 induced metabolic changes. Intriguingly, 
InsR deficient effector T cells were as effective as wt counterparts to induce EAE. A 
closer look at these cells revealed that they don’t express the InsR on the protein 
level anymore. The expression could also not be induced by additional stimulation of 
the cells with neither TCR/CD28 co-stimulation nor with CD28 superagonist- or 
ConA-stimulation. Furthermore, mRNA analysis showed that even the InsR mRNA, 
discussion 
 80 
which is constitutively expressed in resting cells, presumably to allow quick protein 
translation upon activation, is also not expressed in effector T cells. We therefore 
conclude that the InsR is dispensable for long-term activated T cells. 
The cellular metabolism has also impact on T cell function. It has been described that 
there is a link between defective insulin responsiveness and delayed pathogen 
clearance. This might have two reasons: Firstly, the Th cells might be impaired in 
activation and not as functional as their wildtype counterparts. Secondly, a disturbed 
metabolism could interfere with Th lineage commitment and cause false priming of 
the Th cells. To test this issue cytokine profile analysis was performed in our lab. It 
was shown that there is indeed a shift in the Th1/Th2 ratio. qrtPCR analysis indicated 
overall higher IL-2 levels in wt T cells, which is in line with the finding of the impaired 
expression of the autokrine IL-2 receptor CD25. Furthermore it was found that more 
Th1 cytokines such as IFNγ and IL-17A were expressed in InsR deficent cells upon 
co-stimulation compared to wt cells which showed generally higher Th2 cytokine 
levels (IL-4 and IL-10, data of Christopher Sie). There is evidence in the literature 
that this might be a common mechanism of T cell fate decision. Interference with 
metabolism can modulate immune functions. Of note, targeting glucose metabolism 
in mice with the glycolytic inhibitor 2-deoxyglucose was able to suppress EAE (Shi et 
al., 2011) by interfering with Th17 generation. 
In vivo models are more challenging but also more sensitive. A strong stimulation in 
vitro via CD28 could disguise any influence that the InsR deficiency would have 
under physiological conditions. Furthermore, the stimulation is relatively unspecific. If 
the cells were able to be successfully primed after antigen recognition, they would be 
committed to the correct Th lineage and mount a proper immune response. This can 
only be studies using in vivo models. Wrong lineage commitment, e.g. failure to 
generate Th17 cells, would dramatically interfere with a disease model like EAE. A 
general knockdown of the InsR has severe consequences for the entire metabolism. 
The animals develop severe T2DM and have to be sacrificed one week after 
knockdown induction. This is to short for most of the in vivo models, because the 
priming and proliferation of T cells, migration to the target organs and first effector 
mechanisms take about a week. To overcome the problem of a ubiquitous 
knockdown we aimed to generate bone marrow chimeric rats. By sublethal irradiation 
the hematopoietic system of the recipients is destroyed and one day later the animals 
are transplanted with bone marrow of transgenic rats. The graft is able to repopulate 
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the recipient’s immune system and afterwards all cells of hematopoietic origin are 
transgenic while the rest of the body is wildtype. With this approach we have 
generated rats having either eGFP expressing wildtype or InsR deficient 
hematopoietic cells. We induced EAE in these rats 5 days after knockdown induction 
with Dox-containing diet. Surprisingly, we did not observe any differences in the EAE 
course between both genotypes. We therefore had a closer look on the reconstitution 
efficacy. We achieved almost a pure donor genotype in the B cell and granulocyte 
compartment. These cell types, however, can be elided because they are not 
capable of InsR synthesis. With regard to T cells, we ended up having 25-30% 
residual recipient T cells. Although this is a normal rate for T cells in bone marrow 
chimeric rats, it provides a possible explanation why no differences in EAE were 
observed. During EAE immunization the APCs are activated by an inflammatory 
milieu caused by bacterial components implied in the CFA, whereas the T cells are 
stimulated oligoclonally when they recognize their antigen (gpMBP). This is followed 
by massive proliferation of those few cells in the draining lymph nodes. If the InsR 
deficient T cells are impaired in this first step, there can nevertheless be some 
recipient T cells getting activated and subsequently migrate and infiltrate to the CNS 
and cause the EAE lesions despite 70% of the T cells have an impairment. To 
overcome this problem, lymphopenic or T cell deficient rats should be used in the 
future. For the generation of chimeric mice RAG deficient strains are available that 
have no lymphocytes. A prominent example for a lymphopenic rat is the biobreeding 
(BB/OK) rat. This strain has been known for more that 30 years as a model of T1DM 
(Marliss et al., 1982). Both, lymphopenia and disease are caused by a point mutation 
in a single gene, the GTPase of the immune associated proteins 5 (Gimap5) 
(Hornum et al., 2002; MacMurray et al., 2002). For our purpose it is unsuitable 
because of the genetic mismatch between both strains. To generate lymphopenic 
rats on the suitable Lewis background we have backcrossed the BB rat derived 
Gimap5 allele to Lewis rats using speed congenics. First experiments with 
homozygous animals have shown, that these animals are indeed lymphopenic. For 
future experiments these rats should be used as recipients to overcome the problem 
of residual recipient T cells and to reveal potential differences in the immune 
response of InsR deficient lymphocytes. 
As mentiond above, InsR deficiency causes an imbalance between Th1 and Th2 
cells in vitro. There is first line of evidence that changes in the cytokine profile as 
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revealed by qrtPCR are also of relevance in vivo. Blood analysis and intracellular 
staining have shown that re-isolatied donor T cells from our bone marrow chimeric 
rats after EAE induction differ in their IL-17 expression depending on the genotype. 
InsR kd T cells express higher amounts of this cytokine. To validate these findings 
improved chimerism has to be achieved. 
Taken together, the obtained in vitro data indicate that the InsR is important during 
the very first phase of activation before CD134 is expressed. As a drawback, 
TCR/CD28 co-stimulation in vitro is artificial and much stronger than natural antigen-
dependent stimulation. This setting might be too artificial to uncover all effects of 
InsR deficiency. There is also evidence that the InsR plays a role for the balance 
between Th subsets and the appropriate imprinting upon activation. It seems to be 
dispensable for long term activated T cells, although those cells have a glucose-
dependent metabolism. To satisfyingly answer the relevance of the InsR for Th cells 
a more refined in vivo approach has to be established. 
In the future also long-lived memory T cells should be analysed, because their 
metabolic processes are distinct from those of effector T cells (D'Cruz et al., 2009; 
Pearce et al., 2009). Impairment in memory T cell responses might explain the 
increased rate of infections in diabetes patients. Furthermore, T cell culture with 
reduced oxygen in the atmosphere should be conducted. Glycolysis in contrast to 
oxidydative phosphorylation as source of energy in resting cells is oxygen-
independent. Maybe T cells would eventually switch their metabolism if oxygen is 
limited even without CD28 stimulation. Under such conditions up-regulation of the 
InsR might be important to ensure survival of the cells. 
4.3.2. Impact of InsR deficiency on Treg cells 
Malfunction of the suppressive Treg cell compartment is one possible mechanism for 
the link between autoimmunity and metabolic diseases as diabetes. It is known that 
energy supply is an important factor for the fate decision between induced T reg or 
Th17 imprinting (Pearce et al., 2009; Powell et al., 2012). On the other hand it is 
known, that Treg cells just as memory T cells have only a low energy demand, nearly 
on the level of resting cells. Treg cells follow a different dynamics compared to other T 
cell subsets, they express low levels of Glut1, have low glucose uptake and 
glycolysis and gain their energy mostly from lipid oxidation (Barbi et al., 2013). So it 
has to be questioned whether insulin resistance has an influence on Treg cell function. 
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To test this notion, an in vitro suppression assay was performed. In all experiments 
InsR kd and wt Treg did not differ in the capacity to suppress the proliferation of target 
cells. This is in line with the aspect that these cells have an energy demand on the 
level of resting cells which can be easily covered by oxidative phosphorylation or low 
level glycolysis (Barbi et al., 2013).  
A second aspect has to be mentioned. The Treg cells were expanded in vivo prior to 
isolation and during this presumably energy-consuming phase the InsR knockdown 
was not yet completed due to the protocol.  
Collectively, Treg cell function in vitro is independent of InsR presence. Whether it 
might be important during the first activation remains to be elucidated in an in vivo 
approach.  
 
4.3.3. Impact of InsR signalling on cytotoxic T lymphocytes 
Similar to CD4+ T cells, CD8+ CTLs are dependend on glucose as well (Cham et al., 
2008). It has been discovered more than 30 years ago that this T cell subset controls 
its cellular metabolism by co-ordinating oxidative phosphorylation and glycolysis in 
order to meet the energy demand (Greiner et al., 1994; MacDonald, 1977; 
MacDonald and Koch, 1977; MacLennan and Golstein, 1978). Effector CTL have 
higher energy demand than naïve or resting memory CTLs (Cham and Gajewski, 
2005; Cham et al., 2008) and they cover their demand by increased and maintained 
expression of aminoacid transporters and glucose transporters (Fox et al., 2005; 
Jacobs et al., 2008).  
To analyse CTL effector function, we have performed a 51Cr release assay. Hereby it 
was possible to determine the capability of CTLs to kill MHC mismatched cells. We 
have demonstrated a reduced capacity of InsR deficient CTLs to lyse target cells. 
This could in part be explained by the absence of additional activation of Akt through 
InsR engagement, because Akt is central to control CTL function. Activation of Akt by 
PDK1 leads to a down-regulation of CD62L and the chemokine receptor CCR7 
(Waugh et al., 2009). Hereby the enzyme directly interferes with the trafficking of 
effector CTLs compared to naïve cells: Downregulation of both molecules increases 
motility and reduces attraction to lymphoid organs allowing the CTLs to infiltrate to 
target organs.  
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Another possible explanation would be that CTL activity directly requires exocytosis 
and massive generation and degranulation of proteins. InsR engagement might help 
to cover this very high energy demand. 
Future perspectives would be infection studies to see whether the rats are impaired 
in pathogen clearance after infection with intracellular pathogens, i.e. listeria 
monocytogenes. In addition, the role of CD8+ T cell in EAE would be interesting. In 
our setting so far we had up to 30% residual T cells from the host, so an improved 
protocol for the generation of bone marrow chimeric rats was designed making use of 
newly generated lymphopenic Lewis rats (see above). In this context impaired CD8+ 
T cell function might also influence the disease. New finding have revealed, that 
CD8+ T are more important for the priming of effector cells in the periphery then for 
demyelination. Depletion of CD8+ T cells by antibodies or the use of CD8 ko Lewis 
rats lead to a reduction in EAE symptoms, whereas AT-EAE induced with activated 
wt CD4+ T cells in CD8 ko rats was similar compared to wt recipients (Camara et al., 
2013). In our model, a possible reduction of EAE symptoms could be explained in 
two ways. Firstly, CD4+ T cells could be responsible. Since we have shown that long-
term activated effector T cells are not expressing the InsR, amelioration of EAE 
symptoms could be explained by impaired or misdirected priming of the CD4+ T cells. 
Secondly, improved symptoms could be explained by impaired CD8+ T cell function. 
However, careful titration of the antigen and CFA doses will have to be performed to 
elucidate a possible impact of InsR deficiency. A fulminant EAE course could 
disguise effects as also the reduction of EAE symptoms in CD8 ko rats was only 
seen when mild immunization conditions were applied (Camara et al., 2013).  
Another explanation for the impairment of InsR deficient CTLs might be the fact, that 
CD8+ T cells are more sensitive to the stress induced by shRNA expression than 
CD4+ T cells, and that the observed differences between the phenotypes are simply 




Although it has been known that metabolism influences T cell imprinting and function, 
the role of insulin in this context remained elusive. We have shown that the early 
activation of Th cells is impaired in vitro. Surprisingly, the InsR was not only 
dispensable for late activation but was not expressed in long-term activated effector 
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T cells as well (Fig. 33). Also regulatory T cells show normal function under insulin 
resistant conditions. In contrast, CD8+ CTLs showed reduced cytotoxicity if the InsR 
was not expressed, pointing toward a synergistic function of the InsR in meeting the 
energy demands of CTLs during the effector phase. The difference could also be 
explained by CD28, which might compensate for the absence of InsR signalling in 
CD4+, but not in CD8+ T cells. Additionally, both cell types were stimulated differently, 
the artificial stimulation of CD4+ T cells in vitro with anti-CD28 antibody might falsify 
the observed results. 
A prerequisite for all further studies is a satisfying bone marrow chimeric model to 
study the in vivo impacts of missing insulin responsiveness. The hitherto obtained 
results might be an explanation for increased susceptibility to infections. During the 
sensitive process of antigen-dependent T cell activation by APCs it might be 
essential for proper imprinting to the appropriate subset that the cells can respond 
quick and in the right manner. A handicap caused by missing synergistic signalling of 
the InsR could have an impact in vivo (Fig. 33) as first in vitro findings suggest a shift 
of Th subsets.  
Collectively, InsR receptor deficiency mostly impacts of the very first steps of T cell 
activation, namely the priming, followed by energy consuming alterations of the 
cytoskeleton (Fig. 33). When the cells are differentiated the InsR seems to be 
dispensable for covering of energy demands. In this first steps the fate decision takes 
place and if this phase is disturbed it may cause wrong priming of the cells and a shift 




Fig. 33 Dynamics of InsR expression during T cell activation. Upon activation T cells induce InsR 
expression. Deficient insulin signalling impairs expression of the early activation marker CD25. During 








Insulin and GCs are two important endocrine regulators of mammalian body 
homeostasis and both impact on immune cell functions. Whereas GCs are in 
widespread use for the treatment of autoimmune diseases since the late 1950s, the 
influence of insulin is less well characterized. Nonetheless, it is undoubted that there 
is a link between insulin-responsiveness and immunity. Here we have shown that 
GCs exert a rapid effect on T cell morphology. We have identified GC-induced 
phosphorylation of the cytoskeleton associated ERM proteins as an important 
mechanism in this process, and found that it is accompanied by a loss of the 
polarized structure of effector T cells, a reduction in cell size and reduced capacity to 
conjugate with APCs. The effector T cells retract their lammellipodiae following GC 
treatment, which leads to impaired transmigration and presumably chemotaxis, as 
chemokine receptors are expressed in a polarized manner on the lammellipodiae. 
Additionally, we have found that this effect is dependent on the presence of the GR 
and on PLC activity. Furthermore we have challenged the hypothesis that insulin-
responsiveness is required to allow proper T cell activation, differentiation and 
function. We took advantage of an inducible InsR kd to compare the functions and 
the survival of different T cell subsets in the presence or absence of the InsR. We 
could show, that the early phase of T cell activation is impaired in InsR deficient cells, 
whereas the InsR is dispensable during long-term activation and for overall survival. 
Whereas Treg cells were not affected by InsR inactivation, CD8
+ T cells had a 
decreased lytic capacity compared to wildtype cells. So far we have no clear 
evidence whether the InsR also plays a role for immune responses in vivo. 
Collectively, endocrine control of T cell function is of considerable importance and 
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